This page contains the full list of citations for the book Critical Psychiatry Textbook by Peter Gøtzsche, which is being serialized on Mad in America. The chapters are available to read here, with a new chapter becoming available every Monday.
References
1 Whitaker R. Mad in America: bad science, bad medicine, and the enduring mistreatment of the mentally ill. Cambridge: Perseus Books Group; 2002.
2 Healy D. Let them eat Prozac. New York: New York University Press; 2004.
3 Moncrieff J. The myth of the chemical cure: a critique of psychiatric drug treatment. Basingstoke: Palgrave Macmillan; 2007.
4 Moncrieff J. The bitterest pills. Basingstoke: Palgrave Macmillan; 2013.
5 Whitaker R. Anatomy of an epidemic, 2nd edition. New York: Broadway Paperbacks; 2015.
6 Gøtzsche PC. Deadly medicines and organised crime: How big pharma has corrupted health care. London: Radcliffe Publishing; 2013.
7 Gøtzsche PC. Deadly psychiatry and organised denial. Copenhagen: People’s Press; 2015
8 Gøtzsche PC. Mental health survival kit and withdrawal from psychiatric drugs. Ann Arbor: L H Press; 2022.
9 McLaren N. Anxiety, the inside story. How biological psychiatry got it wrong. Ann Arbor: Future Psychiatry Press; 2018.
10 Timimi S. Insane medicine: How the mental health industry creates damaging treatment traps and how you can escape them. Seattle: Kindle Direct Publishing; 2021.
11 Breggin PR. Brain-disabling treatments in psychiatry: drugs, electroshock, and the psychopharmaceutical complex. New York: Springer; 2008.
12 Jorm AF, Korten AE, Jacomb PA, et al. ”Mental health literacy”: a survey of the public’s ability to recognise mental disorders and their beliefs about the effectiveness of treatment. Med J Aus 1997;166:182-6.
13 Kroken RA, Kjelby E, Wentzel-Larsen T, et al. Time to discontinuation of antipsychotic drugs in a schizophrenia cohort: influence of current treatment strategies. Ther Adv Psychopharmacol 2014;4:228-39.
14 Kahneman D. Thinking, fast and slow. London: Penguin Books; 2012.
15 te Meerman S, Batstra L, Freedman JE, Hoekstra, R, Grietens H. ADHD and brain anatomy: What do academic textbooks used in the Netherlands tell students? Children & Society 2019. doi:10.1111/chso.12362.
16 Mors O, Nordentoft M, Hageman I (red.). Klinisk psykiatri. København: Munksgaard; 2016.
17 Simonsen E, Møhl B (red.). Grundbog i psykiatri. København: Hans Reitzels Forlag; 2017.
18 Videbech P, Kjølbye M, Sørensen T, Vestergaard P (red.). Psykiatri. En lærebog om voksnes psykiske sygdomme. København: FADL’s Forlag; 2018.
19 Thomsen PH, Rask CU, Bilenberg N (red.). Børne- og ungdomspsykiatri. København: FADLs Forlag; 2019.
20 Starrfelt R, Gerlach C, Gade A (red.). Klinisk neuropsykologi. København: Frydenlund; 2021.
21 Breggin P. Medication madness. New York: St. Martin’s Griffin; 2008.
22 Rosen RC, Lane RM, Menza M. Effects of SSRIs on sexual function: a critical review. J Clin Psychopharmacol 1999;19:67-85.
23 van Marwijk H, Allick G, Wegman F, et al. Alprazolam for depression. Cochrane Database Syst Rev 2012;7:CD007139.
24 Moncrieff J, Cohen D. Do antidepressants cure or create abnormal brain states? PLoS Med 2006;3:e240.
25 Gonon F. The dopaminergic hypothesis of attention-deficit/hyperactivity disorder needs re-examining. Trends Neurosci 2009;32:2-8.
26 Gøtzsche PC. The Chinese virus: Killed millions and scientific freedom. Antwerp: Global Well, Publishing Services; 2022.
27 Joseph J. Twin studies in psychiatry and psychology: science or pseudoscience? Psychiatr Q 2002;73:71-82.
28 Bouchard TJ Jr, Lykken DT, McGue M, et al. Sources of human psychological differences: the Minnesota Study of Twins Reared Apart. Science 1990 12;250:223-8.
29 Joseph J. A reevaluation of the 1990 “Minnesota Study of Twins Reared Apart” IQ study. Human Development 2022;66:48-65.
30 Tienari P. Interaction between genetic vulnerability and family environment: the Finnish adoptive family study of schizophrenia. Acta Psychiatr Scand 1991;84:460-5.
31 Moncrieff J. Does antipsychotic withdrawal provoke psychosis? Review of the literature on rapid onset psychosis (supersensitivity psychosis) and withdrawal-related relapse. Acta Psychiatrica Scandinavica 2006;114:3-13.
32 Chouinard G. Severe cases of neuroleptic-induced supersensitivity psychosis: diagnostic criteria for the disorder and its treatment. Schizophrenia Research 1990;5:21-33.
33 FDA package insert for Prozac (fluoxetine). Accessed 21 April 2022.
34 FDA package insert for Ritalin (methylphenidate). Accessed 28 April 2022.
35 Varese F, Smeets F, Drukker M, et al. Childhood adversities increase the risk of psychosis: a meta-analysis of patient control, prospective- and cross-sectional cohort studies. Schizophr Bull 2012;38:661-71.
36 Shevlin M, Houston JE, Dorahy MJ, et al. Cumulative traumas and psychosis: an analysis of the national comorbidity survey and the British Psychiatric Morbidity Survey. Schizophr Bull 2008;34:193-9.
37 Kingdon D, Sharma T, Hart D and the Schizophrenia Subgroup of the Royal College of Psychiatrists’ Changing Mind Campaign. What attitudes do psychiatrists hold towards people with mental illness? Psychiatric Bulletin 2004;28:401-6.
38 Zammit S, Allebeck P, David AS, et al. A longitudinal study of premorbid IQ Score and risk of developing schizophrenia, bipolar disorder, severe depression, and other nonaffective psychoses. Arch Gen Psychiatry 2004;61:354-60.
39 Angermeyer MC, Holzinger A, Carta MG, et al. Biogenetic explanations and public acceptance of mental illness: systematic review of population studies. Br J Psychiatry 2011;199:367–72.
40 Read J, Haslam N, Magliano L. Prejudice, stigma and “schizophrenia:” the role of bio-genetic ideology. In: Models of Madness, 2nd Ed. (John Read and Jacqui Dillon, eds.). London: Routledge, 2013.
41 Read J, Haslam N, Sayce L, et al. Prejudice and schizophrenia: a review of the “mental illness is an illness like any other” approach. Acta Psychiatr Scand 2006;114:303-18.
42 Kvaale EP, Haslam N, Gottdiener WH. The ‘side effects’ of medicalization: a meta-analytic review of how biogenetic explanations affect stigma. Clin Psychol Rev 2013;33:782–94.
43 Lebowitz MS, Ahn WK. Effects of biological explanations for mental disorders on clinicians’ empathy. Proc Natl Acad Sci USA 2014;111:17786-90.
44 FDA package insert for Valium (diazepam). Accessed 20 June 2022.
45 Rosenbaum JF, Fava M, Hoog SL, et al. Selective serotonin reuptake inhibitor discontinuation syndrome: a randomised clinical trial. Biol Psychiatry 1998;44:77-87.
46 Gøtzsche PC. Survival in an overmedicated world: look up the evidence yourself. Copenhagen: People’s Press; 2019.
47 Taubes G. Epidemiology faces its limits. Science 1995;269:164–9.
48 Hatch B, Healey DM, Halperin JM. Associations between birth weight and attention-deficit/hyperactivity disorder symptom severity: indirect effects via primary neuropsychological functions. J Child Psychol Psychiatry 2014;55:384-92.
49 Botting N, Powls A, Cooke RW, et al. Attention deficit hyperactivity disorders and other psychiatric outcomes in very low birthweight children at 12 years. J Child Psychol Psychiatry 1997;38:931-41.
50 Deeks JJ, Dinnes J, D’Amico R, et al. Evaluating non-randomised intervention studies. Health Technol Assess 2003;7:1–173.
51 Morrow RL, Garland EJ, Wright JM, et al. Influence of relative age on diagnosis and treatment of attention-deficit/hyperactivity disorder in children. CMAJ 2012;184:755-62.
52 Hahn P. ADHD: The money trail. Mad in America 2022; May 4.
53 Visser SN, Danielson ML, Bitsko RH, et al. Trends in the parent-report of health care provider-diagnosed and medicated attention-deficit/hyperactivity disorder: United States, 2003-2011. J Am Acad Child Adolesc Psychiatry 2014;53:34-46.e2.
54 Williams NM, Zaharieva I, Martin A, et al. Rare chromosomal deletions and duplications in attention-deficit hyperactivity disorder: a genome-wide analysis. Lancet 2010;376:1401-8.
55 Glessner JT, Li J, Wang D, et al. Copy number variation meta-analysis reveals a novel duplication at 9p24 associated with multiple neurodevelopmental disorders. Genome Med 2017;9: 106.
56 Hoogman M, Bralten J, Hibar DP, et al. Subcortical brain volume differences in participants with attention deficit hyperactivity disorder in children and adults: a cross-sectional mega-analysis. Lancet Psychiatry 2017;4:310-9.
57 Whitaker R. Medicating preschoolers for ADHD: How “evidence-based” psychiatry has led to a tragic end. Mad in America 2022; Feb 19.
58 Batstra L, Te Meerman S, Conners K, et al. Subcortical brain volume differences in participants with attention deficit hyperactivity disorder in children and adults. Lancet Psychiatry 2017;4:439.
59 Dehue T, Bijl D, de Winter M, et al. Subcortical brain volume differences in participants with attention deficit hyperactivity disorder in children and adults. Lancet Psychiatry 2017;4:438-9.
60 ADHD & the brain. The American Academy of Child and Adolescent Psychiatry 2017; Feb.
61 Faraone SV, Banaschewski T, Coghill D, et al. The World Federation of ADHD International Consensus Statement: 208 Evidence-based conclusions about the disorder. Neurosci Biobehav Rev 2021;128:789-818.
61 Nunn SPT, Kritsotakis EI, Harpin V, et al. Social gradients in the receipt of medication for attention-deficit hyperactivity disorder in children and young people in Sheffield. B J Psych Open 2020;6:e14.
62 Perroud N, Salzmann A, Prada P, et al. Response to psychotherapy in borderline personality disorder and methylation status of the BDNF gene. Transl Psychiatry 2013;3:e207.
63 Ho BC, Andreasen NC, Ziebell S, et al. Long-term antipsychotic treatment and brain volumes: a longitudinal study of first-episode schizophrenia. Arch Gen Psychiatry 2011;68:128-37.
64 Andreasen NC, Liu D, Ziebell S, et al. Relapse duration, treatment intensity, and brain tissue loss in schizophrenia: a prospective longitudinal MRI study. Am J Psychiatry 2013;170:609-15.
65 Haijma SV, Van Haren N, Cahn W, et al. Brain volumes in schizophrenia: a meta-analysis in over 18 000 subjects. Schizophr Bull 2013;39:1129-38.
66 Videbech P, Ravnkilde B. Hippocampal volume and depression: a meta-analysis of MRI studies. Am J Psychiatry 2004;161:1957-66.
67 Valera EM, Faraone SV, Murray KE, et al. Meta-analysis of structural imaging findings in attention-deficit/hyperactivity disorder. Biol Psychiatry 2007;61:1361-9.
68 Norman LJ, Carlisi C, Lukito S, et al. Structural and functional brain abnormalities in Attention-Deficit/Hyperactivity Disorder and Obsessive-Compulsive Disorder: A comparative meta-analysis. JAMA Psychiatry 2016;73:815-25.
69 Valera EM, Faraone SV, Biederman J, et al. Functional neuroanatomy of working memory in adults with attention-deficit/hyperactivity disorder. Biol Psychiatry 2005;57:439-47.
70 Wager T, Lindquist M, Nichols T, et al. Evaluating the consistency and specificity of neuroimaging data using meta-analysis. NeuroImage 2009;45:S210–21.
71 First M, Botteron K, Carter C, et al. Consensus report of the APA Work Group on Neuroimaging Markers of Psychiatric Disorders. Approved by the Board of Trustees, July 2012.
72 Carp J. The secret lives of experiments: methods reporting in the fMRI literature. NeuroImage 2012;63:289–300.
73 Carp J. On the plurality of (methodological) worlds: estimating the analytic flexibility of FMRI experiments. Front Neurosci 2012;6:149.
74 Botvinik-Nezer R, Holzmeister F, Camerer CF, et al. Variability in the analysis of a single neuroimaging dataset by many teams. Nature 2020;582:84-8.
75 Weinberger DR, Radulescu E. Structural Magnetic Resonance Imaging all over again. JAMA Psychiatry 2021;78:11-2.
76 Marek S, Tervo-Clemmens B, Calabro FJ, et al. Reproducible brain-wide association studies require thousands of individuals. Nature 2022;603:654-60.
77 Simons P. Nature: Brain imaging studies are most likely false. Mad in America 2022; March 21.
78 Barber M. Strengthening research integrity: The role and responsibilities of publishing.
International Science Council 2021; Nov 3.
79 Simons P. People think research is more credible when it includes “extraneous” brain images. Mad in America 2018; May 7.
80 Im S, Varma K, Varma S. Extending the seductive allure of neuroscience explanations effect to popular articles about educational topics. Br J Educ Psychol 2017;87:518-34.
81 Psykiatrien i Region Midtjylland. Updated December 2021, February 2018, March 2022, January 2022, March 2022.
82 France CM, Lysaker PH, Robinson RP. The “chemical imbalance” explanation for depression: origins, lay endorsement, and clinical implications. Professional Psychology: Research and Practice 2007;38:411-20.
83 Schopenhauer A. The art of always being right. London: Gibson Square; 2009.
84 Howes OD, Bose SK, Turkheimer F, Valli I, et al. Dopamine synthesis capacity before onset of psychosis: a prospective [18F]-DOPA PET imaging study. Am J Psychiatry 2011;168:1311-7.
85 Lacasse JR, Leo J. Serotonin and depression: a disconnect between the advertisements and the scientific literature. PLoS Med 2005;2:e392.
86 Hindmarch I. Expanding the horizons of depression: beyond the monoamine hypothesis. Hum Psychopharmacol 2001;16:203-218.
87 Kirsch I. The Emperor’s New Drugs: exploding the antidepressant myth. New York: Basic Books; 2009.
88 Angoa-Pérez M, Kane MJ, Briggs DI, et al. Mice genetically depleted of brain serotonin do not display a depression-like behavioral phenotype. ACS Chem Neurosci 2014;5:908–19.
89 Kessing L, Hansen HV, Demyttenaere K, et al. Depressive and bipolar disorders: patients’ attitudes and beliefs towards depression and antidepressants. Psychol Med 2005;35:1205-13.
90 Demasi M, Gøtzsche PC. Presentation of benefits and harms of antidepressants on websites: cross sectional study. Int J Risk Saf Med 2020;31:53-65.
91 Sterll B. Den psykiatriske epidemi. Psykolognyt 2013;20:8-11.
92 Rasmussen LI. Industriens markedsføring er meget, meget effektiv. Den har fået lægerne til at tro på, at eksempelvis antidepressiva er effektive lægemidler. Det er de overhovedet ikke. Politiken 2015; Aug 30.
93 Depression er en folkesygdom – især for kvinder. Psykiatrifonden 2017; Jan 31.
94 Kessing LV. Depression, hvordan virker medicin. Patienthåndbogen 2015; July 5.
95 Videbech P. SSRI, antidepressivum. Patienthåndbogen 2015; July 23.
96 Read J, Moncrieff J. Depression: why drugs and electricity are not the answer. Psychological Medicine 2022; Febr 1:1–10.
97 Ang B, Horowitz M, Moncrieff J. Is the chemical imbalance an ‘urban legend’? An exploration of the status of the serotonin theory of depression in the scientific literature. SSM Mental Health 2022;2:100098.
98 Köhler O, Benros ME, Nordentoft M, et al. Effect of anti-inflammatory treatment on depression, depressive symptoms, and adverse effects: a systematic review and meta-analysis of randomized clinical trials. JAMA Psychiatry 2014;71:1381-91.
99 Hench PS, Kendall EC, Slocumb CH, et al. The effect of a hormone of the adrenal cortex (17-hydroxy-11-dehydrocorticosterone; compound E) and of pituitary adrenocorticotropic hormone on rheumatoid arthritis. Proc Staff Meet Mayo Clin 1949;24:181-97.
100 Jørgensen FR, Gøtzsche PC, Hein P, et al. Naproxen (Naprosyn) og mobilisering ved behandling af akut ankeldistorsion. Ugeskr Læger 1986;148:1266-8.
101 Gøtzsche PC. Sensitivity of effect variables in rheumatoid arthritis: a meta-analysis of 130 placebo controlled NSAID trials. J Clin Epidemiol 1990;43:1313-8.
102 Caplan PJ. They say you’re crazy: How the world’s most powerful psychiatrists decide who’s normal. Jackson: Da Capo Press, 1995.
103 Dowrick C, Frances A. Medicalising unhappiness: new classification of depression risks more patients being put on drug treatment from which they will not benefit. BMJ 2013;347:f7140.
104 Gøtzsche PC. Surviving psychiatry: a typical case of serious psychiatric drug harms. Mad in America 2020; Jan 7.
105 Gøtzsche PC. Rational diagnosis and treatment. evidence-based clinical decision-making, 4th edition. Chichester: Wiley; 2007.
106 Henkel V, Mergl R, Kohnen R, et al. Identifying depression in primary care: a comparison of different methods in a prospective cohort study. BMJ 2003;326:200-1.
107 Lundh A. [Is there evidence for screening for depression]? Ugeskr Læger 2008;170:1479.
108 Frances A. Saving normal. New York: Harper Collins; 2013.
109 Raven M. Depression and antidepressants in Australia and beyond: a critical public health analysis (PhD thesis). University of Wollongong, Australia; 2012.
110 Kirk SA, Kutchins H. The selling of DSM: the rhetoric of science in psychiatry. New York: Aldine de Gruyter; 1992.
111 Williams JB, Gibbon M, First MB, et al. The Structured Clinical Interview for DSM-III-R (SCID). II. Multisite test-retest reliability. Arch Gen Psychiatry 1992;49:630-6.
112 Watts G. More psychiatrists attack plans for DSM-5. BMJ 2012;344:e3357.
113 Gøtzsche PC. Long-term use of antipsychotics and antidepressants is not evidence-based. Int J Risk Saf Med 2020;31:37-42.
114 Gøtzsche PC. Long-term use of benzodiazepines, stimulants and lithium is not evidence-based. Clin Neuropsychiatry 2020;17:281-3.
115 Mirowski J. Subjective boundaries and combinations in psychiatric diagnoses. J Mind Behav 1990;11:407-24.
116 Moynihan R. Medicalization. A new deal on disease definition. BMJ 2011;342:d2548.
117 Optimal health in a happy society: towards a new biomedical and social model. Global-Well 2022; May 5.
118 Spencer M. The Carter Center’s guide for mental health journalism: don’t question, follow the script. Mad in America 2020; Feb 23.
119 Whitaker R. Den psykiatriske epidemi: Illusionen om mirakelpillen. Søborg: Psykovisions Forlag; 2013.
120 Pedersen AT. En psykiatrisk diagnose hænger ved resten af livet. PsykiatriAvisen 2019; Jan 18.
121 Frandsen P. Et anker af flamingo: Det, vi glemmer, gemmer vi i hjertet. Odense: Mellemgaard; 2019.
122 Bass A. Side effects – a prosecutor, a whistleblower, and a bestselling antidepressant on trial. Chapel Hill: Algonquin Books, 2008.
123 Angell M. “The illusions of psychiatry”: an exchange. New York Review of Books 2011; Aug 18.
124 Barbui C, Cipriani A, Brambilla P, et al. ”Wish bias” in antidepressant drug trials? J Clin Psychopharmacol 2004;24:126-30.
125 Hughes S, Cohen D, Jaggi R. Differences in reporting serious adverse events in industry sponsored clinical trial registries and journal articles on antidepressant and antipsychotic drugs: a cross-sectional study. BMJ Open 2014;4:e005535.
126 Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiat 1960;23:56-62.
127 Fisher S, Greenberg RG. How sound is the double-blind design for evaluating psychotropic drugs? J Nerv Ment Dis 1993;181:345-50.
128 Angell M. The truth about the drug companies: How they deceive us and what to do about it. New York: Random House, 2004.
129 Moynihan R, Cassels A. Selling sickness: How the world’s biggest pharmaceutical companies are turning us all into patients. New York: Nation Books, 2005.
130 Gøtzsche PC, Dinnage O. What have antidepressants been tested for? A systematic review. Int J Risk Saf Med 2020;31:157-63.
131 Petersen M. Our daily meds. New York: Sarah Crichton Books; 2008.
132 Larson JC, Ensrud KE, Reed SD, et al. Efficacy of escitalopram for hot flashes in healthy menopausal women: a randomized controlled trial. JAMA 2011;305:267-74.
133 Boyd R. A view from the man in the seat opposite. BMJ 1998;317:410.
134 FDA package insert for Zyprexa (olanzapine). Accessed 5 May 2022.
135 Breggin P. Psychiatric drug withdrawal: A guide for prescribers, therapists, patients and their families. New York: Springer; 2012.
136 Davies J, Read J. A systematic review into the incidence, severity and duration of antidepressant withdrawal effects: Are guidelines evidence-based? Addict Behav 2019;97:111-21.
137 Chan A-W, Hróbjartsson A, Haahr MT, et al. Empirical evidence for selective reporting of outcomes in randomized trials: comparison of protocols to published articles. JAMA 2004;291:2457-65.
138 Gøtzsche PC, Hróbjartsson A, Johansen HK, et al. Constraints on publication rights in industry-initiated clinical trials. JAMA 2006;295:1645-6.
139 Bassler D, Briel M, Montori VM, et al. Stopping randomized trials early for benefit and estimation of treatment effects: systematic review and meta-regression analysis. JAMA 2010;303:1180-7.
140 Gøtzsche PC, Hrobjartsson A, Johansen HK, et al. Ghost authorship in industry-initiated randomised trials. PLoS Med 2007;4:e19.
141 Healy D, Cattell D. Interface between authorship, industry and science in the domain of therapeutics. Br J Psychiatry 2003;183:22-7.
142 Healy D. Shaping the intimate: influences on the experience of everyday nerves. Soc Stud Sci 2004;34/2:219-45.
143 Smith R. Time to assume that health research is fraudulent until proven otherwise? BMJ 2021;July 5.
144 Carlisle JB. False individual patient data and zombie randomised controlled trials submitted to Anaesthesia. Anaesthesia 2021;76:472-9.
145 Roberts I, Ker K, Edwards P, et al. The knowledge system underpinning healthcare is not fit for purpose and must change. BMJ 2015;350:h2463.
146 Gøtzsche PC. The decline and fall of the Cochrane empire. Copenhagen: Institute for Scientific Freedom; 2022. Freely available book.
147 Kirk SA, Gomory T, Cohen D. Mad science: psychiatric coercion, diagnosis and drugs. New Brunswick: Transaction Publishers; 2013.
148 Gronfein W. Psychotropic drugs and the origins of deinstitutionalization. Social Problems 1985;32:437-54.
149 Leucht S, Tardy M, Komossa K, et al. Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. Lancet 2012;379:2063-71.
150 Danborg PB, Gøtzsche PC. Benefits and harms of antipsychotic drugs in drug-naïve patients with psychosis: A systematic review. Int J Risk Saf Med 2019;30:193-201.
151 Wang CH, Li Y, Yang J, et al. A randomized controlled trial of olanzapine improving memory deficits in Han Chinese patients with first-episode schizophrenia. Schizophr Res 2013;144:129-35.
152 Khin NA, Chen YF, Yang Y, et al. Exploratory analyses of efficacy data from schizophrenia trials in support of new drug applications submitted to the US Food and Drug Administration. J Clin Psychiatry 2012;73:856-64.
153 Francey SM, O’Donoghue B, Nelson B, et al. Psychosocial intervention with or without antipsychotic medication for first episode psychosis: a randomized noninferiority clinical trial. Schizophr Bull Open 2020; Mar 20. https://doi.org/10.1093/schizbullopen/sgaa015.
154 Bola J, Kao D, Soydan H, et al. Antipsychotic medication for early episode schizophrenia. Cochrane Database Syst Rev 2011;6:CD006374.
155 Cole JO. Phenothiazine treatment in acute schizophrenia; effectiveness: the National Institute of Mental Health Psychopharmacology Service Center Collaborative Study Group. Arch Gen Psychiatry 1964;10:246-61.
156 Leucht S, Kane JM, Etschel E, et al. Linking the PANSS, BPRS, and CGI: clinical implications. Neuropsychopharmacology 2006;31:2318-25.
157 Samara MT, Klupp E, Helfer B, et al. Increasing antipsychotic dose for non response in schizophrenia. Cochrane Database Syst Rev 2018;5:CD011883.
158 Belmaker RH, Wald D. Haloperidol in normals. Br J Psychiatry 1977;131:222-3.
159 Breggin PR. Intoxication anosognosia: the spellbinding effect of psychiatric drugs. Ethical Hum Psychol Psychiatry 2006;8:201–15.
160 Moncrieff J, Cohen D, Mason JP. The subjective experience of taking antipsychotic medication: a content analysis of Internet data. Acta Psychiatr Scand 2009;120:102-11.
161 Whitaker R. Lure of riches fuels testing. Boston Globe 1998; Nov 17.
162 Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA 2005;294:1934–43.
163 FDA package insert for Risperdal (risperidone). Accessed 30 May 2022.
164 Koponen M, Taipale H, Lavikainen P, et al. Risk of mortality associated with antipsychotic monotherapy and polypharmacy among community-dwelling persons with Alzheimer’s disease. J Alzheimers Dis 2017;56:107-18.
165 Dold M, Li C, Tardy M, et al. Benzodiazepines for schizophrenia. Cochrane Database Syst Rev 2012;11:CD006391.
166 Gøtzsche PC. Psychiatry ignores an elephant in the room. Mad in America 2017; Sept 21.
167 Hegelstad WT, Larsen TK, Auestad B, et al. Long-term follow-up of the TIPS early detection in psychosis study: effects on 10-year outcome. Am J Psychiatry 2012;169:374-80.
168 Melle I, Olav Johannesen J, Haahr UH, et al. Causes and predictors of premature death in first-episode schizophrenia spectrum disorders. World Psychiatry 2017;16:217-8.
169 Wils RS, Gotfredsen DR, Hjorthøj C, et al. Antipsychotic medication and remission of psychotic symptoms 10 years after a first-episode psychosis. Schizophr Res 2017;182:42-8.
170 Prien RF, Levine J, Switalski RW. Discontinuation of chemotherapy for chronic schizophrenics. Hospital and Community Psychiatry 1971;22:20-3.
171 Crowner ML, Douyon R, Convit A, et al. Akathisia and violence. Psychopharmacol Bull 1990;26:115-7.
172 Medawar C. The antidepressant web – marketing depression and making medicines work. Int J Risk Saf Med 1997;10:75-126.
173 Haro JM, Novick D, Bertsch J, et al. Cross-national clinical and functional remission rates: Worldwide Schizophrenia Outpatient Health Outcomes (W-SOHO) study. Br J Psychiatry 2011;199:194-201.
174 Harrow M, Jobe TH, Tong L. Twenty-year effects of antipsychotics in schizophrenia and affective psychotic disorders. Psychol Med 2021;Feb 8:1-11. doi: 10.1017/S0033291720004778.
175 Timimi S. Children’s mental health in the era of globalisation: neo-liberalism, commodification, Mcdonaldisation, and the new challenges they pose. In: Victor Olisah (ed), Essential Notes in Psychiatry; 2012. Available from: http://www.intechopen.com/books.
176 Seikkula J, AaltonenJ, Alakare B, et al. Five-year experience of first-episode nonaffective psychosis in open-dialogue approach: Treatment principles, follow-up outcomes, and two case studies. Psychotherapy Research 2006;16:214-28.
177 Svedberg B, Mesterton A, Cullberg J. First-episode non-affective psychosis in a total urban population: a 5-year follow-up. Soc Psychiatry Psychiatr Epidemiol 2001;36:332-7.
178 Pharoah F, Mari J, Rathbone J, et al. Family intervention for schizophrenia. Cochrane Database Syst Rev 2010;12:CD000088.
179 Kinoshita Y, Furukawa TA, Kinoshita K, et al. Supported employment for adults with severe mental illness. Cochrane Database Syst Rev 2013;9:CD008297.
180 Bighelli I, Rodolico A, García-Mieres et al. Psychosocial and psychological interventions for relapse prevention in schizophrenia: a systematic review and network meta-analysis. Lancet Psychiatry 2021;8:969-80.
181 Chatterton ML, Stockings E, Berk M, et al. Psychosocial therapies for the adjunctive treatment of bipolar disorder in adults: network meta-analysis. Br J Psychiatry 2017;210:333-341.
182 Dieterich M, Irving CB, Bergman H, et al. Intensive case management for severe mental illness. Cochrane Database Syst Rev 2017;1:CD007906.
183 Duncan E, Best C, Hagen S. Shared decision making interventions for people with mental health conditions. Cochrane Database Syst Rev 2010;1:CD007297.
184 United Nations Convention on the Rights of Persons with Disabilities: General comment No. 1. 2014; May 19.
185 Marshall M, Rathbone J. Early intervention for psychosis. Cochrane Database Syst Rev 2011;6:CD004718.
186 Kirkpatrick B, Fenton WS, Carpenter WT Jr, et al. The NIMH-MATRICS consensus statement on negative symptoms. Schizophr Bull 2006;32:214-9.
187 Rummel‐Kluge C, Kissling W, Leucht S. Antidepressants for the negative symptoms of schizophrenia. Cochrane Database Syst Rev 2006;3:CD005581.
188 Whitehead C, Moss S, Cardno A, et al. Antidepressants for people with both schizophrenia and depression. Cochrane Database Syst Rev 2002;2:CD002305.
189 Gøtzsche PC. Psychiatry gone astray. Mad in America 2014; Jan 28.
190 Arbejdsmiljø og behandlingsformer i den danske psykiatri. Nordjyske Medier 2007.
191 Ilyas S, Moncrieff J. Trends in prescriptions and costs of drugs for mental disorders in England, 1998-2010. Br J Psychiatry 2012;200:393-8.
192 Wunderink L, Nieboer RM, Wiersma D, et al. Recovery in remitted first-episode psychosis at 7 years of follow-up of an early dose reduction/discontinuation or maintenance treatment strategy: long-term follow-up of a 2-year randomized clinical trial. JAMA Psychiatry 2013;70:913-20.
193 Hui CLM, Honer WG, Lee EHM, et al. Long-term effects of discontinuation from antipsychotic maintenance following first-episode schizophrenia and related disorders: a 10 year follow-up of a randomised, double-blind trial. Lancet Psychiatry 2018;5:432-42.
194 Chen EY, Hui CL, Lam MM, et al. Maintenance treatment with quetiapine versus discontinuation after one year of treatment in patients with remitted first episode psychosis: randomised controlled trial. BMJ 2010;341:c4024.
195 Gøtzsche PC. Sundhedsstyrelsens farlige råd om depressionspiller. Politikens Kronik 2010; Feb 7.
196 Spielmans GI, Parry PI. From evidence-based medicine to marketing-based medicine: evidence from internal industry documents. Bioethical Inquiry 2010. DOI 10.1007/s11673-010-9208-8.
197 Healy D. Pharmageddon. Berkeley: University of California Press; 2012.
198 Jackson GE. An analysis of the olanzapine clinical trials – dangerous drug, dubious efficacy. PsychRights 2003; March 3.
199 Gottstein J. The Zyprexa papers. Anchorage: Jim Gottstein; 2020.
200 Larsen N-E. Ny medicin har betydelige bivirkninger. Dagens Medicin 2001; Sept 27.
201 The largest pharma fraud whistleblower case in U.S. history totaling $1.4 billion. Reuters 2009; Jan 15.
202 Berenson A. Eli Lilly said to play down risk of top pill. New York Times 2006; Dec 7.
203 Transparency International. Global Corruption Report 2006.
204 McGauran N, Wieseler B, Kreis J et al. Reporting bias in medical research – a narrative review. Trials 2010;11:37.
205 Khan H, Thomas P. Drug giant AstraZeneca to pay $520 million to settle fraud case. ABC News 2010; Apr 27.
206 Ark. judge fines Johnson & Johnson more than $1.1B in Risperdal case. CBS/AP 2012; Apr 11.
207 Harris G. Research center tied to drug company. New York Times 2008; Nov 25.
208 Kelton E. J&J needs a cure: new CEO allegedly had links to fraud. Forbes 2012; Apr 17.
209 Insel TR. Psychiatrists’ relationships with pharmaceutical companies: part of the problem or part of the solution? JAMA 2010;303:1192-3.
210 Mello MM, Clarridge BR, Studdert DM. Academic medical centers standards for clinical-trial agreements with industry. N Engl J Med 2005;352:2202–10.
211 Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 2003;60:553-64.
212 Heres S, Davis J, Maino K, et al. Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: an exploratory analysis of head-to-head comparison studies of second-generation antipsychotics. Am J Psychiatry 2006;163:185–94.
213 Geddes J, Freemantle N, Harrison P, et al. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ 2000;321:1371-6.
214 Leucht S, Corves C, Arbter D, et al. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 2009;373:31–41.
215 Tyrer P, Kendall T. The spurious advance of antipsychotic drug therapy. Lancet 2009;373:4–5.
216 Pagsberg AK, Tarp S, Glintborg D, et al. Acute antipsychotic treatment of children and adolescents with schizophrenia-spectrum disorders: a systematic review and network meta-analysis. J Am Acad Child Adolesc Psychiatry 2017;56:191-202.
217 Hutton B, Salanti G, Caldwell DM, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med 2015;162:777-84.
218 Désaméricq G, Schurhoff F, Meary A, et al. Long-term neurocognitive effects of antipsychotics in schizophrenia: a network meta-analysis. Eur J Clin Pharmacol 2014;70:127-34.
219 FDA package insert for Clozaril (clonazepine). Accessed 5 May 2022.
220 Li CR, Chung YC, Park TW, et al. Clozapine-induced tardive dyskinesia in schizophrenic patients taking clozapine as a first-line antipsychotic drug. World J Biol Psychiatry 2009;10:919-24.
221 Asenjo Lobos C, Komossa K, Rummel-Kluge C, et al. Clozapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev 2010;11:CD006633.
222 Meltzer HY, Alphs L, Green AI, et al. Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Arch Gen Psychiatry 2003;60:82-91.
223 Joukamaa M, Heliövaara M, Knekt P. Schizophrenia, neuroleptic medication and mortality. Br J Psychiatry 2006;188:122-7.
224 Tenback D, Pijl B, Smeets H. All-cause mortality and medication risk factors in schizophrenia. J Clin Psychopharmacol 2012;32:31-5.
225 Waddington JL, Youssef HA, Kinsella A. Mortality in schizophrenia. Antipsychotic polypharmacy and absence of adjunctive anticholinergics over the course of a 10-year prospective study. Br J Psychiatry 1998;173:325-9.
226 Ray WA, Meredith S, Thapa PB, et al. Antipsychotics and the risk of sudden cardiac death. Arch Gen Psychiatry 2001;58:1161-7.
227 Ray WA, Chung CP, Murray KT, et al. Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med 2009;360:225-35.
228 Forbruget af antipsykotika blandt 18-64 årige patienter, med skizofreni, mani eller bipolar affektiv sindslidelse. København: Sundhedsstyrelsen; 2006.
229 Marston L, Nazareth I, Petersen I, et al. Prescribing of antipsychotics in UK primary care: a cohort study. BMJ Open 2014;4:e006135.
230 Olfson M, Blanco C, Liu SM, et al. National trends in the office-based treatment of children, adolescents, and adults with antipsychotics. Arch Gen Psychiatry 2012;69:1247-5.
231 Agovino T. Antipsychotic drug use among kids soars. Drugs 2006; May 2.
232 Saha S, Chant D, McGrath J. A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time? Arch Gen Psychiatry 2007;64:1123-31.
233 Khan A, Faucett J, Morrison S, et al. Comparative mortality risk in adult patients with schizophrenia, depression, bipolar disorder, anxiety disorders, and attention-deficit/hyperactivity disorder participating in psychopharmacology clinical trials. JAMA Psychiatry 2013;70:1091-9.
234 Christensen DC. Dear Luise: a story of power and powerlessness in Denmark’s psychiatric care system. Portland: Jorvik Press; 2012.
235 Dorph-Petersen KA, Pierri JN, Perel JM, et al. The influence of chronic exposure to antipsychotic medications on brain size before and after tissue fixation: a comparison of haloperidol and olanzapine in macaque monkeys. Neuropsychopharmacology 2005;30:1649-61.
236 Raduaa J, Borgwardt S, Crescinid A, et al. Multimodal meta-analysis of structural and functional brain changes in first episode psychosis and the effects of antipsychotic medication. Neurosci Biobehav Rev 2012;36:2325–33.
237 Zipursky RB, Reilly TJ, Murray RM. The myth of schizophrenia as a progressive brain disease. Schizophr Bull 2013;39:1363-72.
238 Pagsberg AK, Baaré WF, Raabjerg Christensen AM, et al. Structural brain abnormalities in early onset first-episode psychosis. J Neural Transm 2007;114:489-98.
239 Manschreck TC, Boshes RA. The CATIE schizophrenia trial: results, impact, controversy. Harv Rev Psychiatry 2007;15:245-58.
240 What does akathisia and tardive dyskinesia look like? Videos of children and adults who have been permanently brain damaged by neuroleptics. Deadlymedicines website, undated.
241 Moncrieff J. Antipsychotic maintenance treatment: time to rethink? PLoS Med 2015;12:e1001861.
242 Karon BP. All I know about Peter Breggin. In: The International Center for the Study of Psychiatry and Psychology. The Conscience of Psychiatry. The reform work of Peter R. Breggin, MD. New York: Lake Edge Press; 2009.
243 Weiden PJ, Mann JJ, Haas G, et al. Clinical nonrecognition of neuroleptic-induced movement disorders: a cautionary study. Am J Psychiatry 1987;144:1148-53.
244 Berna F, Misdrahi D, Boyer L, et al. Akathisia: prevalence and risk factors in a community-dwelling sample of patients with schizophrenia. Results from the FACE-SZ dataset. Schizophr Res 2015;169:255-261.
245 Tachere RO, Modirrousta M. Beyond anxiety and agitation: A clinical approach to akathisia. Aust Fam Phys 2017;46(5).
246 Moskowitz PE. Breaking off my chemical romance. The Nation 2022; Mar 23.
247 Hjorthøj CR, Madsen T, Agerbo E, et al. Risk of suicide according to level of psychiatric treatment: a nationwide nested case-control study. Soc Psychiatry Psychiatr Epidemiol 2014;49:1357-65.
248 Large MM, Ryan CJ. Disturbing findings about the risk of suicide and psychiatric hospitals. Soc Psychiatry Psychiatr Epidemiol 2014;49:1353-5.
249 Leucht S, Helfer B, Dold M, et al. Lithium for schizophrenia. Cochrane Database Syst Rev 2015;10:CD003834.
250 Mosher LR, Vallone R, Menn A. The treatment of acute psychosis without neuroleptics: Six week psychopathology outcome data from the Soteria project. Int J Soc Psych 1995;41:157‐73.
251 Read J. A history of madness. In: Read J, Dillon J, eds. Models of madness, 2nd ed. London: Routledge; 2013.
252 Psychosis and schizophrenia in adults: prevention and management. Clinical guideline [CG178]. NICE 2014; Feb 12.
253 Morrison AP, Turkington D, Pyle M, et al. Cognitive therapy for people with schizophrenia spectrum disorders not taking antipsychotic drugs: a single-blind randomised controlled trial. Lancet 2014;383:1395-403.
254 Leucht S, Cipriani A, Spineli L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple treatments meta-analysis. Lancet 2013;382:951–62.
255 Morbidity and Mortality Weekly Report. Current depression among adults – United States, 2006 and 2008. JAMA 2010;304:2233-5.
256 Leader D. The creation of the Prozac myth. The Guardian 2008; Feb 27.
257 A new epidemic (motivational deficiency disorder). YouTube 2006; Nov 24.
258 Moynihan R. Scientists find new disease: motivational deficiency disorder. BMJ 2006;332:745.
259 Coombes R. Having the last laugh at big pharma. BMJ 2007;334:396-7.
260 HAVIDOL: female testimonial. YouTube 2007; Feb 5.
261 Minutes of the Pediatric Advisory Committee. FDA 2006; Mar 22.
262 Martin A, Young C, Leckman JF et al. Age effects on antidepressant-induced manic conversion. Arch Pediatr Adolesc Med 2004;158:773-80.
264 Nielsen M, Gøtzsche P. An analysis of psychotropic drug sales. Increasing sales of selective serotonin reuptake inhibitors are closely related to number of products. Int J Risk Saf Med 2011;23:125–32.
265 Pirraglia PA, Stafford RS, Singer DE. Trends in prescribing of selective serotonin reuptake inhibitors and other newer antidepressant agents in adult primary care. Prim Care Companion J Clin Psychiatry 2003;5:153-7.
266 Moncrieff J, Wessely S, Hardy R. Active placebos versus antidepressants for depression. Cochrane Database Syst Rev 2004;1:CD003012.
267 Leucht S, Fennema H, Engel R, et al. What does the HAMD mean? J Affect Disord 2013;148:243-8.
268 Jakobsen JC, Katakam KK, Schou A, et al. Selective serotonin reuptake inhibitors versus placebo in patients with major depressive disorder. A systematic review with meta-analysis and Trial Sequential Analysis. BMC Psychiatry 2017;17:58.
269 Kirsch I, Deacon BJ, Huedo-Medina TB, et al. Initial severity and antidepressant benefits: A meta-analysis of data submitted to the Food and Drug Administration. PLoS Med 2008;5:e45.
270 Fournier JC, DeRubeis RJ, Hollon SD, et al. Antidepressant drug effects and depression severity: a patient-level meta-analysis. JAMA 2010;303:47-53.
271 Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet 2018;391:1357-66.
272 Gøtzsche PC, Gøtzsche PK. Cognitive behavioural therapy halves the risk of repeated suicide attempts: systematic review. J R Soc Med 2017;110:404-10.
273 Gibbons RD, Hur K, Brown CH, et al. Benefits from antidepressants: synthesis of 6-week patient-level outcomes from double-blind placebo-controlled randomized trials of fluoxetine and venlafaxine. Arch Gen Psychiatry 2012;69:572-9.
274 Hróbjartsson A, Gøtzsche PC. Is the placebo powerless? An analysis of clinical trials comparing placebo with no treatment. N Engl J Med 2001;344:1594-602.
275 FDA package insert for Lexapro (escitalopram). Accessed 18 April 2022.
276 Miller M, Swanson SA, Azrael D, et al. Antidepressant dose, age, and the risk of deliberate self-harm. JAMA Intern Med 2014;174:899-909.
277 Healy D, Herxheimer A, Menkes DB. Antidepressants and violence: problems at the interface of medicine and law. PLoS Med 2006;3:e372.
278 FDA package insert for Celexa (citalopram). Accessed 18 April 2022.
279 Gøtzsche PC, Healy D. Restoring the two pivotal fluoxetine trials in children and adolescents with depression. Int J Risk Saf Med 2022; Pre-press, DOI: 10.3233/JRS-210034.
280 Mosholder AD. Application number: 18-936/SE5-064. Medical review. FDA 2001; 4 Oct.
281 Horowitz MA, Taylor D. Tapering of SSRI treatment to mitigate withdrawal symptoms. Lancet Psychiatry 2019;6:538-46.
282 Benkert O, Szegedi A, Wetzel H, et al. Dose escalation vs. continued doses of paroxetine and maprotiline: a prospective study in depressed out-patients with inadequate treatment response. Acta Psychiatr Scand 1997;95:288-96.
283 Kirsch I, Moore TJ, Scoboria, A, et al. The emperor’s new drugs: An analysis of antidepressant medication data submitted to the U.S. Food and Drug Administration. Prevention & Treatment 2002;5:Article 23.
284 Bech P, Kajdasz DK, Porsdal V. Dose-response relationship of duloxetine in placebo-controlled clinical trials in patients with major depressive disorder. Psychopharmacology 2006;188:273-80.
285 Santaguida P, MacQueen G, Keshavarz H, et al. Treatment for depression after unsatisfactory response to SSRIs. Comparative Effectiveness Review No. 62. (Prepared by McMaster University Evidence-based Practice Center under Contract No. HHSA 290 2007 10060 I.) AHRQ Publication No.12-EHC050-EF. Rockville, MD: Agency for Healthcare Research and Quality 2012; April.
286 Hieronymus F, Nilsson S, Eriksson E. A mega-analysis of fixed-dose trials reveals dose-dependency and a rapid onset of action for the antidepressant effect of three selective serotonin reuptake inhibitors. Transl Psychiatry 2016;6:e834.
287 Rink L, Braun C, Bschor T, et al. Dose increase versus unchanged continuation of antidepressants after initial antidepressant treatment failure in patients with major depressive disorder: a systematic review and meta-analysis of randomized, double-blind trials. J Clin Psychiatry 2018;79:17r11693.
288 UK citalopram Summary of Product Characteristics. Accessed 20 April 2022.
289 UK fluoxetine Summary of Product Characteristics. Accessed 20 April 2022.
290 UK paroxetine Summary of Product Characteristics. Accessed 20 April 2022.
291 Benkert O, Szegedi A, Wetzel H, et al. Dose escalation vs. continued doses of paroxetine and maprotiline: a prospective study in depressed out-patients with inadequate treatment response. Acta Psychiatr Scand 1997;95:288-96.
292 Meyer JH, Wilson AA, Sagrati S, et al. Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: an [11C]DASB positron emission tomography study. Am J Psychiatry 2004;161:826-35.
293 Guyatt G, Cairns J, Churchill D, et al. Evidence-based medicine: A new approach to teaching the practice of medicine. JAMA 1992;268:2420-5.
294 Williams NR, Heifets BD, Blasey B, et al. Opioid receptor antagonism attenuates antidepressant effects of ketamine. Am J Psychiatry 2018;175:1205–15.
295 Jauhar S, Morrison P. Esketamine for treatment resistant depression. We should cautiously welcome this new therapeutic option. BMJ 2019;366:l5572.
296 Gøtzsche PC, Hengartner MP, Davies J, et al. Esketamine for treatment resistant depression. BMJ 2019; Oct 3.
297 Cipriani A, Zhou X, Del Giovane C, et al. Comparative efficacy and tolerability of antidepressants for major depressive disorder in children and adolescents: a network meta-analysis. Lancet 2016;388:881-90.
298 Mazereeuw G, Sullivan MD, Juurlink DN. Depression in chronic pain: might opioids be responsible? Pain 2018;159:2142-5.
299 Fuentes JJ, Fonseca F, Elices M, et al. Therapeutic use of LSD in psychiatry: a systematic review of randomized-controlled clinical trials. Front Psychiatry 2020;10:943.
300 Le Noury J, Nardo JM, Healy D, et al. Restoring Study 329: efficacy and harms of paroxetine and imipramine in treatment of major depression in adolescence. BMJ 2015;351:h4320.
301 Sharma T, Guski LS, Freund N, et al. Drop-out rates in placebo-controlled trials of antidepressant drugs: A systematic review and meta-analysis based on clinical study reports. Int J Risk Saf Med 2019;30:217-32.
302 Nutt DJ, Goodwin GM, Bhugra D, et al. Attacks on antidepressants: signs of deep-seated stigma? Lancet Psychiatry 2014;1:103–4.
303 Laughren TP. Overview for December 13 Meeting of Psychopharmacologic Drugs Advisory Committee (PDAC). FDA 2006; Nov 16.
304 Nielsen M, Hansen EH, Gøtzsche PC. Dependence and withdrawal reactions to benzodiazepines and selective serotonin reuptake inhibitors. How did the health authorities react? Int J Risk Saf Med 2013;25:155-68.
305 Michelson D, Fava M, Amsterdam J, et al. Interruption of selective serotonin reuptake inhibitor treatment. Double-blind, placebo-controlled trial. Br J Psychiatry 2000;176:363-8.
306 Korsgaard P, Jensen JH. [Drug maker: nonsense! Denies dependence on happy pills: It isn’t possible]. Ekstra Bladet 2012; Dec 11.
307 Medawar C, Hardon A. Medicines out of control? Antidepressants and the conspiracy of goodwill. Holland: Aksant Academic Publishers; 2004.
308 Read J, Cartwright C, Gibson K. Adverse emotional and interpersonal effects reported by 1829 New Zealanders while taking antidepressants. Psychiatry Res 2014;216:67-73.
309 Bockting CL, ten Doesschate MC, Spijker J, et al. Continuation and maintenance use of antidepressants in recurrent depression. Psychother Psychosom 2008;77:17-26.
310 Dependence and withdrawal associated with some prescribed medications: an evidence review. Public Health England 2019; Sept.
311 Gøtzsche PC. Why I think antidepressants cause more harm than good. Lancet Psychiatry 2014;1:104-6 (available at www.deadlymedicines.dk).
312 Moncrieff J. A straight talking introduction to psychiatric drugs. Ross-on-Wye: PCCS Books; 2009.
313 Davies J. Cracked: Why psychiatry is doing more harm than good. London: Icon Books; 2013.
314 Melander H, Ahlqvist-Rastad J, Meijer G, et al. Evidence b(i)ased medicine – selective reporting from studies sponsored by pharmaceutical industry: review of studies in new drug applications. BMJ 2003;326:1171–3.
315 Turner EH, Matthews AM, Linardatos E, et al. Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med 2008;358:252-60.
316 Mosholder AD. Application number: 18-936/SE5-064. Statistical review. FDA 2001; 20 July.
317 Gøtzsche PC. Restoring invisible and abandoned trials: a call for people to publish the findings. BMJ 2019; May 6.
318 Nilsson M, Joliat MJ, Miner CM, Brown EB, Heiligenstein JH. Safety of subchronic treatment with fluoxetine for major depressive disorder in children and adolescents. J Child Adolesc Psychopharmacol 2004;14:412-7.
319 Tauscher-Wisniewski S, Nilsson M, Caldwell C, et al. Meta-analysis of aggression and/or hostility-related events in children and adolescents treated with fluoxetine compared with placebo. J Child Adolesc Psychopharmacol 2007;17:713-8.
320 Barczyk ZA, Rucklidge JJ, Eggleston M, et al. Psychotropic medication prescription rates and trends for New Zealand children and adolescents 2008-2016. J Child Adolesc Psychopharmacol 2020;30:87-96.
321 UNICEF Office of Research. Building the future: children and the sustainable development goals in rich countries. Innocenti ReportCard 14; 2017.
322 March J, Silva S, Petrycki S, et al. Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial. JAMA 2004;292:807-20.
323 Aboustate N, Jureidini J. Barriers to access to clinical trial data: obstruction of a RIAT reanalysis of the Treatment for Adolescents with Depression Study. Int J Risk Saf Med 2021 Oct 26. doi: 10.3233/JRS-210022. Epub ahead of print.
324 Westergren T, Narum S, Klemp M. Adverse effects information in clinical guidelines on pharmacological treatment of depression in children and adolescents: A systematic review. BMJ Open 2020;10:e036412.
325 Högberg G, Antonuccio DO, Healy D. Suicidal risk from TADS study was higher than it first appeared. Int J Risk Saf Med 2015;27:85-91.
326 Sharma T, Guski LS, Freund N, et al. Suicidality and aggression during antidepressant treatment: systematic review and meta-analyses based on clinical study reports. BMJ 2016;352:i65.
327 Jensen PS, Ryan ND, Prien R. Psychopharmacology of child and adolescent major depression: present status and future directions. J Child Adolesc Psychopharmacol 1992;2:31-45.
328 Healy D. The antidepressant era. Cambridge: Harvard University Press; 1997.
329 Locher C, Koechlin H, Zion SR, et al. Efficacy and safety of selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, and placebo for common psychiatric disorders among children and adolescents: a systematic review and meta-analysis. JAMA Psychiatry 2017;74:1011-20.
330 A Letter from Russell Katz to GlaxoSmithKline. 2002; 21 Oct.
331 Keller MB, Ryan ND, Strober M, et al. Efficacy of paroxetine in the treatment of adolescent major depression: a randomized, controlled trial. J Am Acad Child Adolesc Psychiatry 2001;40:762-72.
332 Jureidini JN, McHenry LB. Conflicted medical journals and the failure of trust. Accountability in Research 2001;18:45–54.
333 Healy D, LeNoury J, Wood J. Children of the cure. Toronto: Samizdat Writers Co-operative; 2020.
334 Jureidini JN, McHenry LB, Mansfield PR. Clinical trials and drug promotion: selective reporting of study 329. Int J Risk Safety Med 2008;20:73-81.
335 More fraud from drug giant GlaxoSmithKline companies – court documents show. Child Health Safety 2010; Dec 1.
336 FDA package insert for Paxil (paroxetine). Accessed 23 May 2022.
337 Friedman RA. Antidepressants’ black-box warning – 10 years later. N Engl J Med 2014;371:1666-8.
338 Hammad TA, Laughren T, Racoosin J. Suicidality in pediatric patients treated with antidepressant drugs. Arch Gen Psychiatry 2006;63:332-9.
339 Meier B. Contracts keep drug research out of reach. New York Times 2004; Nov 29.
340 Relman AS, Angell M. America’s other drug problem: how the drug industry distorts medicine and politics. The New Republic 2002; Dec 16:27-41.
341 Boseley S. Junket time in Munich for the medical profession – and it’s all on the drug firms. The Guardian 2004; Oct 5.
342 Lars Kessing i Aftenshowet. DR1 2013; Apr 15.
343 Brownlee S. Overtreated: why too much medicine is making us sicker and poorer. New York: Bloomsbury; 2007.
344 Boseley S. They said it was safe. The Guardian 1999; Oct 30.
345 Breggin P. Talking back to Prozac. New York: E-reads, 1994.
346 Internal Eli Lilly memo. Bad Homburg 1984; May 25.
347 Spielmans GI, Gerwig K. The efficacy of antidepressants on overall well-being and self-reported depression symptom severity in youth: a meta-analysis. Psychother Psychosom 2014;83:158–64.
348 Hetrick SE, McKenzie JE, Cox GR, et al. Newer generation antidepressants for depressive disorders in children and adolescents. Cochrane Database Syst Rev 2012;11:CD004851.
349 Greenberg RP, Bornstein RF, Greenberg MD, et al. A meta-analysis of antidepressant outcome under “blinder” conditions. J Consult Clin Psychol 1992;60:664-9.
350 Virapen J. Side effects: death. College Station: Virtualbookworm.com Publishing; 2010.
351 Pringle E. Eli Lilly hides data: Zyprexa, Evista, Prozac risk. Conspiracy Planet (accessed 28 June 2012).
352 Teicher MH, Glod C, Cole JO. Emergence of intense suicidal preoccupation during fluoxetine treatment. Am J Psychiatry 1990;147:207-10.
353 Lenzer J. FDA to review “missing” drug company documents. BMJ 2005;330:7.
354 Lenzer J. Drug secrets: what the FDA isn’t telling. Slate 2005; Sept 27.
355 Lenzer J. Secret US report surfaces on antidepressants in children. BMJ
2004;329:307.
356 Walsh BT, Seidman SN, Sysko R, et al. Placebo response in studies of major depression: variable, substantial, and growing. JAMA 2002;287:1840-7.
357 Jurand SH. Lawsuits over antidepressants claim the drug is worse than the disease. American Association for Justice 2003; Mar 1.
358 GlaxoSmithKline. Wikipedia (accessed 20 June 2012).
359 Herxheimer A. Turbulence in UK medicines regulation: A stink about SSRI antidepressants that isn’t going away. Chapter 10. In: Glavanis K, O’Donovan O (eds). Power, politics and pharmaceuticals: drug regulation in Ireland in the global context. Cork University Press; 2008.
360 Medawar C, Herxheimer A. A comparison of adverse drug reaction reports from professionals and users, relating to risk of dependence and suicidal behaviour with paroxetine. Int J Risk Saf Med 2003/2004;16:5-19.
361 Grassley CE. Paxil. Speech at the US Senate 2008; June 11.
362 Stipp D. Trouble in Prozac. CNN Money 2005; Nov 28.
363 Lenzer J. Crisis deepens at the US Food and Drug Administration. BMJ 2004;329:1308.
364 Healy D. SSRIs and deliberate self-harm. Br J Psychiatry 2002;180:547.
365 Healy D. Did regulators fail over selective serotonin reuptake inhibitors? BMJ 2006;333:92-5.
366 Khan A, Warner HA, Brown WA. Symptom reduction and suicide risk in patients treated with placebo in antidepressant clinical trials: an analysis of the Food and Drug Administration database. Arch Gen Psychiatry 2000;57:311-7.
367 Power N, Lloyd K. Response from Pfizer. Br J Psychiatry 2002;180:547-8.
368 Rockhold F, Metz A, Traber P. Response from GlaxoSmithKline. Br J Psychiatry 2002;180:548.
369 Boseley S. Scandal of scientists who take money for papers ghostwritten by drug companies. The Guardian 2002; Feb 7.
370 Furukawa TA. All clinical trials must be reported in detail and made publicly available. Lancet 2004;329:626.
371 FDA. Antidepressant use in children, adolescents, and adults. Accessed 22 Apr 2014.
372 European Medicines Agency (1999/2000). EMEA/CPMP/2775/99.
373 Laughren TP. The scientific and ethical basis for placebo-controlled trials in depression and schizophrenia: an FDA perspective. Eur Psychiatry 2001;16:418-23.
374 Eli Lilly memo. Suicide report for BGA. Bad Homburg 1990; Aug 3.
375 Briefing Document. Paroxetine adult suicidality analysis: major depressive disorder and non-major depressive disorder. GlaxoSmithKline 2006; Apr 5.
376 Important prescribing information. GlaxoSmithKline 2006; May.
377 Bielefeldt AØ, Danborg PB, Gøtzsche PC. Precursors to suicidality and violence on antidepressants: systematic review of trials in adult healthy volunteers. J R Soc Med 2016;109:381-92.
378 Maund E, Guski LS, Gøtzsche PC. Considering benefits and harms of duloxetine for treatment of stress urinary incontinence: a meta-analysis of clinical study reports. CMAJ 2017;189:E194-203.
379 FDA. Historical Information on duloxetine hydrochloride (marketed as Cymbalta) (accessed 30 June, 2022).
380 Vanderburg DG, Batzar E, Fogel I, et al. A pooled analysis of suicidality in double-blind, placebo-controlled studies of sertraline in adults. J Clin Psychiatry 2009;70:674-83.
381 Gunnell D, Saperia J, Ashby D. Selective serotonin reuptake inhibitors (SSRIs) and suicide in adults: meta-analysis of drug company data from placebo controlled, randomised controlled trials submitted to the MHRA’s safety review. BMJ 2005;330:385.
382 Fergusson D, Doucette S, Glass KC, et al. Association between suicide attempts and selective serotonin reuptake inhibitors: systematic review of randomised controlled trials. BMJ 2005;330:396.
383 Montejo A, Llorca G, Izquierdo J, et al. Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients. Spanish Working Group for the study of psychotropic-related sexual dysfunction. J Clin Psychiatry 2001;62 (suppl 3):10–21.
384 Hengartner MP, Plöderl M. Newer-generation antidepressants and suicide risk in randomized controlled trials: a re-analysis of the FDA database. Psychother Psychosom 2019;88:247-8.
385 Hengartner MP, Plöderl M. Reply to the Letter to the Editor: “Newer-Generation Antidepressants and Suicide Risk: Thoughts on Hengartner and Plöderl’s ReAnalysis.” Psychother Psychosom 2019;88:373-4.
386 Gøtzsche PC. Åbent brev til Lundbeck om antidepressiva og selvmord. Videnskab dk 2011; July 7.
387 Pedersen AG. Lundbecks svar på Peter Gøtzsches åbne brev om antidepressiva og selvmord. Videnskab.dk 2001; July 8.
388 Beautrais AL. Suicide and serious suicide attempts in youth: a multiple-group comparison study. Am J Psychiat 2003;160:1093–9.
389 Michel K. Suicide risk factors: a comparison of suicide attempters with suicide completers. Br J Psychiatry 1987;150:78-82.
390 159 FDA package insert for Lyrica (pregabalin). Accessed 29 April 2022.
391 Gibbons RD, Brown CH, Hur K, et al. Early evidence on the effects of regulators’ suicidality warnings on SSRI prescriptions and suicide in children and adolescents. Am J Psychiatry 2007;164:1356-63.
392 Whitaker R. The triumph of bad science. Mad in America 2012; July 11.
393 Hjelmeland H, Jaworski K, Knizek BL, et al. Problematic advice from suicide prevention experts. Ethical Human Psychology and Psychiatry 2018;20:79-85.
394 Whitaker R, Blumke D. Screening + drug treatment = increase in veteran suicides. Mad in America 2019; Nov 10.
395 Erlangsen A, Lind BD, Stuart EA, et al. Short-term and long-term effects of psychosocial therapy for people after deliberate self-harm: a register-based, nationwide multicentre study using propensity score matching. Lancet Psychiatry 2015;2:49-58.
396 Hawton K, Witt KG, Taylor Salisbury TL, et al. Psychosocial interventions for self-harm in adults. Cochrane Database Syst Rev 2016;5:CD012189.
397 Videos from International meeting: Psychiatric drugs do more harm than good. Copenhagen 2015; Sept 16.
398 Gøtzsche PC. Usage of depression pills almost halved among children in Denmark. Mad in America 2018; May 4.
399 Gøtzsche PC. National boards of health are unresponsive to children driven to suicide by depression pills. Mad in America 2020; Mar 15.
400 Frankfurt HG. On bullshit. New Jersey: Princeton University Press; 2005.
401 Moore TJ, Glenmullen J, Furberg CD. Prescription drugs associated with reports of violence towards others. PLoS One 2010;5:e15337.
402 Lucire Y, Crotty C. Antidepressant-induced akathisia-related homicides associated with diminishing mutations in metabolizing genes of the CYP450 family. Pharmgenomics Pers Med 2011;4:65–81.
403 Paxil maker held liable in murder/suicide. Baum & Hedlund 2001; July 9.
404 Boseley S. Murder, suicide. A bitter aftertaste for the ’wonder’ depression drug. Guardian 2011; June 11.
405 SSRI Stories: antidepressant nightmares. Accessed 10 June 2022.
406 Kessing LV, Nilsson FM. Increased risk of developing dementia in patients with major affective disorders compared to patients with other medical illnesses. J Affect Disord 2003;73:261-9.
407 Ownby RL, Crocco E, Acevedo A, et al. Depression and risk for Alzheimer disease: systematic review, meta-analysis, and meta-regression analysis. Arch Gen Psychiatry 2006;63:530-8.
408 Videbech P. Debatten om antidepressiv medicin – Virker det, og bliver man afhængig? BestPractice Psykiatri/Neurologi 2014; May:nr. 25.
409 Healy D, Le Noury J, Mangin D. Enduring sexual dysfunction after treatment with antidepressants, 5α-reductase inhibitors and isotretinoin: 300 cases. Int J Risk Saf Med 2018;29:125-34.
410 Healy D. Antidepressants and sexual dysfunction: a history. J R Soc Med 2020;113:133-5.
411 Csoka AB, Bahrick A, Mehtonen OP. Persistent sexual dysfunction after discontinuation of selective serotonin reuptake inhibitors. J Sex Med 2008;5:227-33.
412 Maciag D, Simpson KL, Coppinger D, et al. Neonatal antidepressant exposure has lasting effects on behavior and serotonin circuitry. Neuropsychopharmacology 2006;31:47–57.
413 Simonsen AL, Danborg PB, Gøtzsche PC. Persistent sexual dysfunction after early exposure to SSRIs: Systematic review of animal studies. Int J Risk Saf Med 2016;28:1-12.
414 Healy D, Le Noury J, Mangin D. Post-SSRI sexual dysfunction: Patient experiences of engagement with healthcare professionals. Int J Risk Saf Med 2019;30:167-78.
415 Paludan-Müller AS, Sharma T, Rasmussen K, et al. Extensive selective reporting of quality of life in clinical study reports and publications of placebo-controlled trials of antidepressants. Int J Risk Saf Med 2021;32:87-99.
416 Stemningsstabiliserende medicin. Psykiatrien i Region Midtjylland 2022; Jan.
417 Biederman J, Faraone S, Mick E, et al. Attention-deficit hyperactivity disorder and juvenile mania: an overlooked comorbidity? J Am Acad Child Adolesc Psychiatry 1996;35:997-1008.
418 Parry PI, Allison S, Bastiampillai T. Reification of the paediatric bipolar hypothesis in the USA. Lancet Psychiatry 2015;2:14-6.
419 Offidani E, Fava GA, Tomba E, et al. Excessive mood elevation and behavioral activation with antidepressant treatment of juvenile depressive and anxiety disorders: a systematic review. Psychother Psychosom 2013;82:132-41.
420 Baldessarini RJ, Faedda GL, Offidani E, et al. Antidepressant-associated mood switching and transition from unipolar major depression to bipolar disorder: a review. J Affect Disord 2013;148:129-35.
421 Geddes JR, Burgess S, Hawton K, et al. Long-term lithium therapy for bipolar disorder: systematic review and meta-analysis of randomized controlled trials. Am J Psychiatry 2004;161:217-22.
422 Christodoulou GN, Lykouras EP. Abrupt lithium discontinuation in manic-depressive patients Acta Psychiat Scand 1982;65:310-314.
423 Suppes T, Baldessarini RJ, Faedda GL, et al. Risk of recurrence following discontinuation of lithium treatment in bipolar disorder. Arch Gen Psychiatry 1991;48:1082-8.
424 Cavanagh J, Smyth R, Goodwin GM. Relapse into mania or depression following lithium discontinuation: a 7-year follow-up. Acta Psychiatr Scand 2004;109:91-5.
425 Baldessarini RJ, Tondo L, Faedda GL, et al. Effects of the rate of discontinuing lithium maintenance treatment in bipolar disorders. J Clin Psychiatry 1996;57:441-8.
426 Baldessarini RJ, Tondo L, Hennen J. Effects of lithium treatment and its discontinuation on suicidal behavior in bipolar manic-depressive disorders. J Clin Psychiatry 1999;60 Suppl 2:77-84; discussion 111-6.
427 Baldessarini RJ, Tondo L, Viguera AC. Discontinuing lithium maintenance treatment in bipolar disorders: risks and implications. Bipolar Disord 1999;1:17-24.
428 Börjesson J, Gøtzsche PC. Effect of lithium on suicide and mortality in mood disorders: A systematic review. Int J Risk Saf Med 2019;30:155-66.
429 Cipriani A, Hawton K, Stockton S, et al. Lithium in the prevention of suicide in mood disorders: updated systematic review and meta-analysis. BMJ 2013;346:f3646.
430 Kessing LV, Søndergård L, Kvist K, et al. Suicide risk in patients treated with lithium. Arch Gen Psychiatry 2005;62:860-6.
431 Baastrup PC, Schou M. Lithium as a prophylactic agents. Its effect against recurrent depressions and manic-depressive psychosis. Arch Gen Psychiatry 1967;16:162-72.
432 Jacobs DG, Baldessarini RJ, Conwell Y, et al. Work group on suicidal behaviors. Practice guideline for the assessment and treatment of patients with suicidal behaviors. 2003.
433 Baldessarini RJ, Tondo L, Davis P, et al. Decreased risk of suicides and attempts during long-term lithium treatment: a meta-analytic review. Bipolar Disord 2006;8:625-39.
434 Lauterbach E, Felber W, Müller-Oerlinghausen B, et al. Adjunctive lithium treatment in the prevention of suicidal behaviour in depressive disorders: a randomised, placebo-controlled, 1-year trial. Acta Psychiatr Scand 2008;118:469-79.
435 Gøtzsche PC. Blinding during data analysis and writing of manuscripts. Controlled Clin Trials 1996;17:285-90.
436 McKnight RF, de La Motte SJ, Chesney E, et al. Lithium for acute mania. Cochrane Database Syst Rev 2019;6:CD0040.
437 FDA package insert for lithium. Accessed 25 April 2022.
438 Rendell JM, Gijsman HJ, Keck PK, et al. Olanzapine alone or in combination for acute mania. Cochrane Database Syst Rev 2003;1:CD004040.
439 FDA package insert for Neurontin (gabapentin). Accessed 4 Jan 2020.
440 Dickersin K. Reporting and other biases in studies of Neurontin for migraine, psychiatric/bipolar disorders, nociceptive pain, and neuropathic pain. Pharmalot.com (accessed 10 Dec 2008).
441 Vedula SS, Bero L, Scherer RW, et al. Outcome reporting in industry-sponsoredt rials of gabapentin for off-label use. N Engl J Med 2009;361:1963-71.
442 Landefeld CS, Steinman MA. The Neurontin legacy – marketing through misinformation and manipulation. N Engl J Med 2009;360:103-6.
443 Voris B, Lawrence J. Pfizer Told to Pay $142.1 million for Neurontin Fraud. Bloomberg 2010; Mar 25.
444 Tansey B. Huge penalty in drug fraud / Pfizer settles felony case in Neurontin off-label promotion. San Francisco Chronicle 2004; May 14.
445 Vasudev A, Macritchie K, Watson S, et al. Oxcarbazepine in the maintenance treatment of bipolar disorder. Cochrane Database Syst Rev 2008;1:CD005171.
446 Cipriani A, Reid K, Young AH, et al. Valproic acid, valproate and divalproex in the maintenance treatment of bipolar disorder. Cochrane Database Syst Rev 2013;10:CD003196.
447 Coupland C, Dhiman P, Morriss R, et al. Antidepressant use and risk of adverse outcomes in older people: population based cohort study. BMJ 2011;343:d4551.
448 Leipzig RM, Cumming RG, Tinetti ME. Drugs and falls in older people: a systematic review and meta-analysis: I. Psychotropic drugs. J Am Geriatr Soc 1999;47:30-9.
449 Kripke DF, Langer RD, Kline LE. Hypnotics’ association with mortality or cancer: a matched cohort study. BMJ Open 2012;2:e000850.
450 Glass J, Lanctôt KL, Herrmann N, et al. Sedative hypnotics in older people with insomnia: meta-analysis of risks and benefits. BMJ 2005;331:1169-73.
451 Hemmelgarn B, Suissa S, Huang A, et al. Benzodiazepine use and the risk of motor vehicle crash in the elderly. JAMA 1997;278:27-31.
452 Hubbard R, Farrington P, Smith C, et al. Exposure to tricyclic and selective serotonin reuptake inhibitor antidepressants and the risk of hip fracture. Am J Epidemiol 2003;158:77-84.
453 Thapa PB, Gideon P, Cost TW, et al. Antidepressants and the risk of falls among nursing home residents. N Engl J Med 1998;339:875-82.
454 Lewinsohn PM, Clarke GN, Seeley, et al. Major depression in community adolescents: age at onset, episode duration, and time to recurrence. J Am Acad Child Adolesc Psychiatr 1994;33:809-18.
455 Karle J, Bauer J. Vildledning om medicin mod depression. Politiken 2011; Apr 1.
456 Gøtzsche PC. Rewarding the companies that cheated the most in antidepressant trials. Mad in America 2018; Mar 7.
457 Hickie IB, Rogers NL. Novel melatonin-based therapies: potential advances in the treatment of major depression. Lancet 2011;378:621-31.
458 Koesters M, Guaiana G, Cipriani A, et al. Agomelatine efficacy and acceptability revisited: systematic review and meta-analysis of published and unpublished randomised trials. Br J Psychiatry 2013;203:179-87.
459 Gorman JM, Korotzer A, Su G. Efficacy comparison of escitalopram and citalopram in the treatment of major depressive disorder: pooled analysis of placebo-controlled trials. CNS Spectr 2002;7(4 Suppl. 1):40-4.
460 Escitalopram (Lexapro) for depression. Medical Letter 2002;44:83-4.
461 Dyer O. Lundbeck broke advertising rules. BMJ 2003;326:1004.
462 Cipriani A, Santilli C, Furukawa TA et al. Escitalopram versus other antidepressive agents for depression. Cochrane Database Syst Rev 2009;2:CD006532.
463 Carlsen LT. En svær balance. Tænk + Test 2003;32:30-3.
464 Lindberg M. Interessant hensyn til eksporten. Dagens Medicin 2002; Nov 29.
465 Lægemiddelstyrelsen giver Lundbeck medvind. Politiken 2004; Sept 13.
466 Behandling med antidepressiva. Institut for Rationel Farmakoterapi 2004; Sept 10.
467 Antitrust: Commission fines Lundbeck and other pharma companies for delaying market entry of generic medicines. European Commission Press release 2013; June 19.
468 Alkhafaji AA, Trinquart L, Baron G, et al. Impact of evergreening on patients and health insurance: a meta-analysis and reimbursement cost analysis of citalopram/escitalopram antidepressants. BMC Med 2012;10:142.
469 Drug maker Forest pleads guilty; to pay more than $313 million to resolve criminal charges and False Claims Act allegations. US Department of Justice 2010; Sept 15.
470 Hyltoft V. Lundbeck-partner i forlig om selvmord. Berlingske 2011;Feb 8.
471 Meier B, Carey B. Drug maker is accused of fraud. New York Times 2009; Feb 25.
472 Edwards J. Suit vs. Forest Labs names execs linked to alleged lies about Lexapro, Celexa. CBS News, Moneywatch 2009; Feb 26.
473 Jackson T. Are you being duped? BMJ 2001;322:1312.
474 Kassirer JP. On the take: how medicine’s complicity with big business can endanger your health. Oxford: Oxford University Press; 2005.
475 Carlat D. Dr drug rep. New York Times 2007; Nov 25.
476 Letter about Lexapro documents. US Senate, Committee on Finance 2009; Aug 12.
477 Cosgrove L, Vannoy S, Mintzes B, et al. Under the influence: the interplay among industry, publishing, and drug regulation. Account Res 2017;24:99-115.
478 Trinquart L, Abbé A, Ravaud P. Impact of reporting bias in network meta-analysis of antidepressant placebo-controlled trials. PLoS ONE 2012;7:e35219.
479 Therrien A. Anti-depressants: Major study finds they work. BBC News 2018; Feb 22.
480 Munkholm K, Paludan-Müller AS, Boesen K. Considering the methodological limitations in the evidence base of antidepressants for depression: a reanalysis of a network meta-analysis. BMJ Open 2019;9:e024886.
481 Higgins JPT, Green S (eds.). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration 2011.
482 Karen Thisted fik mod på livet: lykkepillerne der virker. Region Hovedstaden Bibtex 2018; Mar 26.
483 Healy D, Mangin D, Mintzes B. The ethics of randomized placebo controlled trials of antidepressants with pregnant women. Int J Risk Saf Med 2010;22:7-16.
484 Healy D, Le Noury J, Mangin D. Links between serotonin reuptake inhibition during pregnancy and neurodevelopmental delay/spectrum disorders: A systematic review of epidemiological and physiological evidence. Int J Risk Saf Med 2016;28:125-41.
485 Referenceprogram for unipolar depression hos voksne. København: Sundhedsstyrelsen; 2007.
486 Levinson-Castiel R, Merlob P, Linder N et al. Neonatal abstinence syndrome after in utero exposure to selective serotonin reuptake inhibitors in term infants. Arch Pediatr Adolesc Med 2006;160:173-6.
487 Pedersen LH, Henriksen TB, Vestergaard M, et al. Selective serotonin reuptake inhibitors in pregnancy and congenital malformations: population based cohort study. BMJ 2009;339:b3569.
488 Gøtzsche PC. Screening pregnant women for depression. Mad in America 2014; May 5.
489 Gøtzsche PC. Deadly medicines and organised crime. YouTube 2013; Oct 18.
490 Anvendelse af psykofarmaka ved graviditet og amning: kliniske retningslinjer. Dansk Psykiatrisk Selskab, Dansk Selskab for Obstetrik og Gynækologi, Dansk Pædiatrisk Selskab, Dansk Selskab for Klinisk Farmakologi 2014; Oct 27.
491 Pearson RM, Evans J, Kounali D, et al. Maternal depression during pregnancy and the postnatal period: risks and possible mechanisms for offspring depression at age 18 years. JAMA Psychiatry 2013;70:1312-9.
492 Pedersen LH, Henriksen TB, Bech BH, et al. Prenatal antidepressant exposure and behavioral problems in early childhood – a cohort study. Acta Psychiatr Scand 2013;127:126-35.
493 Sun X, Briel M, Busse JW et al. The influence of study characteristics on reporting of subgroup analyses in randomised controlled trials: systematic review. BMJ 2011;342:d1569.
494 Priest RG, Vize C, Roberts A, et al. Lay people’s attitudes to treatment of depression: results of opinion poll for Defeat Depression Campaign just before its launch. BMJ 1996;313:858-9.
495 Stubbe DE, Thomas WT. A survey of early-career child and adolescent psychiatrists: professional activities and perceptions. J Am Acad Child Adolesc Psychiatry 2002;41:123–30.
496 Heldmark T. Alternativ behandling mot depression används för lite. Sveriges Radio 2020; Aug 24.
497 McPherson S, Hengartner MP. Long-term outcomes of trials in the National Institute for Health and Care Excellence depression guideline. BJPsych Open 2019;5:e81.
498 Spielmans GI, Berman MI, Usitalo AN. Psychotherapy versus second-generation antidepressants in the treatment of depression: a meta-analysis. J Nerv Ment Dis 2011;199:142–9.
499 Cuijpers P, Hollon SD, van Straten A, et al. Does cognitive behaviour therapy have an enduring effect that is superior to keeping patients on continuation pharmaco-therapy? A meta-analysis. BMJ Open 2013;26;3(4).
500 Shedler J. The efficacy of psychodynamic psychotherapy. Am Psychol 2010;65:98-109.
501 Furukawa TA, Shinohara K, Sahker E, et al. Initial treatment choices to achieve sustained response in major depression: a systematic review and network meta-analysis. World Psychiatry 2021;20:387-96.
502 Churchill R, Hunot V, Corney R, et al. A systematic review of controlled trials of the effectiveness and cost-effectiveness of brief psychological treatments for depression. Health Technol Assess 2001;5(35).
503 Amick HR, Gartlehner G, Gaynes BN, et al. Comparative benefits and harms of second generation antidepressants and cognitive behavioral therapies in initial treatment of major depressive disorder: systematic review and meta-analysis. BMJ 2015;351:h6019.
504 Non-farmakologisk behandling af unipolar depression. National klinisk retningslinje. København: Sundhedsstyrelsen; 2019.
505 Colom F, Vieta E, Martinez-Aran A, et al. A randomized trial on the efficacy of group psychoeducation in the prophylaxis of recurrences in bipolar patients whose disease is in remission. Arch Gen Psychiatry 2003;60:402-7.
506 National Institutes of Health Consensus Development Conference Statement: diagnosis and treatment of attention-deficit/hyperactivity disorder (ADHD). J Am Acad Child Adolesc Psychiatry 2000:39:182-93.
507 Looking Back at the 1998 NIH Consensus Conference: Pediatrician Dr. Mark Vonnegut at a loss for words, defining ADHD as “children who can’t sit still” (accessed 29 April 2014).
508 Whitely M. ADHD is BS. YouTube video.
509 Adult ADHD Self-Report Scale-V1.1 (ASRS-V1.1) Symptoms Checklist from WHO Composite International Diagnostic Interview; 2003.
510 Lopez PL, Torrente FM, Ciapponi A, et al. Cognitive‐behavioural interventions for attention deficit hyperactivity disorder (ADHD) in adults. Cochrane Database Syst Rev 2018;3:CD010840.
511 Storebø OJ, Ramstad E, Krogh HB, et al. Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD). Cochrane Database Syst Rev 2015;11:CD009885.
512 Aagaard L, Hansen EH. The occurrence of adverse drug reactions reported for attention deficit hyperactivity disorder (ADHD) medications in the pediatric population: a qualitative review of empirical studies. Neuropsychiatr Dis Treat 2011;7:729-44.
513 Boesen K, Paludan-Müller AS, Gøtzsche PC, et al. Extended-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults. Cochrane Database Syst Rev 2022;2:CD012857.
514 Epstein T, Patsopoulos NA, Weiser M. Immediate-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults. Cochrane Database Syst Rev 2014;9:CD005041.
515 Boesen K, Saiz LC, Erviti J, et al. The Cochrane Collaboration withdraws a review on methylphenidate for adults with attention deficit hyperactivity disorder. Evid Based Med 2017;22:143-7.
516 The MTA Cooperative Group. A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Arch Gen Psychiatry 1999;56:1073-86.
517 Jensen PS, Arnold LE, Swanson JM, et al. 3-year follow-up of the NIMH MTA study. J Am Acad Child Adolesc Psychiatry 2007;46:989-1002.
518 Molina BS, Flory K, Hinshaw SP, et al. Delinquent behavior and emerging substance use in the MTA at 36 months: prevalence, course, and treatment effects. J Am Acad Child Adolesc Psychiatry 2007;46:1028-40.
519 Nadine Lambert. Wikipedia (accessed 29 April 2022).
520 Frost J. Ritalin may cause children to smoke early, abuse stimulants as adults, UC Berkeley professor says. University of California, Berkeley 1999; May 5.
521 Molina BS, Hinshaw SP, Swanson JM, et al. The MTA at 8 years: prospective follow-up of children treated for combined-type ADHD in a multisite study. J Am Acad Child Adolesc Psychiatry 2009;48:484-500.
522 Miranda C. ADHD drugs could stunt growth. Daily Telegraph 2007; Nov 12.
523 Vedantam S. Debate over drugs for ADHD reignites. Washington Post 2009; Mar 27.
524 Swanson JM, Arnold LE, Molina BSG, et al. Young adult outcomes in the follow-up of the multimodal treatment study of attention-deficit/hyperactivity disorder: symptom persistence, source discrepancy, and height suppression. J Child Psychol Psychiatry 2017;58:663-78.
525 Borcherding BG, Keysor CS, Rapoport JL, et al. Motor/vocal tics and compulsive behaviors on stimulant drugs: is there a common vulnerability? Psychiatry Res 1990;33:83-94.
526 Breggin PR. The rights of children and parents in regard to children receiving psychiatric diagnoses and drugs. Children & Society 2014;28:231-41.
527 Danborg PB, Simonsen AL, Gøtzsche PC. Impaired reproduction after exposure to ADHD drugs: Systematic review of animal studies. Int J Risk Saf Med 2017;29:107-24.
528 Cherland E, Fitzpatrick R. Psychotic side effects of psychostimulants: a 5-year review. Can J Psychiatry 1999;44:811-3.
529 Jensen PS, Hinshaw SP, Swanson JM, et al. Findings from the NIMH Multimodal Treatment Study of ADHD (MTA): implications and applications for primary care providers. J Dev Behav Pediatr 2001;22:60-73.
530 Connor DF, Glatt SJ, Lopez ID, Jackson D, et al. Psychopharmacology and aggression. I: A meta-analysis of stimulant effects on overt/covert aggression-related behaviors in ADHD. J Am Acad Child Adolesc Psychiatry 2002;41:253-61.
531 Asherson P. Drug treatments for ADHD reduce risk of substance use disorders. Am J Psychiatry 2017;174:827-8.
532 Özgen H, Spijkerman R, Noack M, et al. Treatment of adolescents with concurrent substance use disorder and Attention-Deficit/Hyperactivity Disorder: a systematic review. J Clin Med 2021;10:3908.
533 Whitaker R, Gøtzsche PC. The pervasive financial and scientific corruption of psychiatric drug trials. Copenhagen: Institute for Scientific Freedom 2022: Mar 23.
534 Faraone SV, Glatt SJ. A comparison of the efficacy of medications for adult attention-deficit/hyperactivity disorder using meta-analysis of effect sizes. J Clin Psychiatry 2010;71:754-63.
535 Altman DG, Royston P. The cost of dichotomising continuous variables. BMJ 2006;332:1080.
536 Dalsgaard S, Mortensen PB, Frydenberg M, et al. Long-term criminal outcome of children with attention deficit hyperactivity disorder. Crim Behav Ment Health 2013;23:86-98.
537 Dalsgaard S, Mortensen PB, Frydenberg M, et al. ADHD, stimulant treatment in childhood and subsequent substance abuse in adulthood – a naturalistic long-term follow-up study. Addict Behav 2014;39:325-8.
538 Adams M. Neurologist Dr. Fred Baughman talks about the fraud of ADHD and the poisoning of U.S. children. Natural News 2006; Aug 30.
539 Canada regulators order ADD drug withdrawn. Associated Press 2015; Feb 10.
540 WHO. Management of substance abuse. Amphetamine-like substances. Undated (accessed 14 March 2020).
541 What is the scope of methamphetamine misuse in the United States? National Institute on Drug Abuse 2019; Oct.
542 Wallach-Kildemoes H, Skovgaard AM, Thielen K, et al. Social adversity and regional differences in prescribing of ADHD medication for school-age children. J Dev Behav Pediatr 2015;36:330-41.
543 Xu G, Strathearn L, Liu B, et al. Twenty-year trends in diagnosed Attention-Deficit/Hyperactivity Disorder among US children and adolescents, 1997-2016. JAMA Netw Open 2018;1:e181471.
544 Shoptaw SJ, Kao U, Heinzerling K, et al. Treatment for amphetamine withdrawal. Cochrane Database Syst Rev 2009;2:CD003021.
545 Haug TT, Blomhoff S, Hellstrøm K, et al. Exposure therapy and sertraline in social phobia: 1-year follow-up of a randomised controlled trial. Br J Psychiatry 2003;182:312–8.
546 James AC, James G, Cowdrey FA, et al. Cognitive behavioural therapy for anxiety disorders in children and adolescents. Cochrane Database Syst Rev 2015;2:CD004690.
547 Boer PCAM, Wiersma D, Russo S, et al. Paraprofessionals for anxiety and depressive disorders. Cochrane Database Syst Rev 2005;2:CD004688.
548 Mayo-Wilson E, Montgomery P. Media-delivered cognitive behavioural therapy and behavioural therapy (selfhelp) for anxiety disorders in adults. Cochrane Database Syst Rev 2013;9:CD005330.
549 Gava I, Barbui C, Aguglia E, et al. Psychological treatments versus treatment as usual for obsessive compulsive disorder (OCD). Cochrane Database Syst Rev 2007;2:CD005333.
550 Soomro GM, Altman DG, Rajagopal S, et al. Selective serotonin re-uptake inhibitors (SSRIs) versus placebo for obsessive compulsive disorder (OCD). Cochrane Database Syst Rev 2008;1:CD001765.
551 O’Kearney RT, Anstey KJ, von Sanden C. Behavioural and cognitive behavioural therapy for obsessive compulsive disorder in children and adolescents. Cochrane Database Syst Rev 2006;4:CD004856.
552 Referenceprogram for angstlidelser hos voksne. København: Sundhedsstyrelsen; 2007.
553 National Institute for Clinical Excellence. Obsessive-compulsive disorder: Core interventions in the treatment of obsessive-compulsive disorder and body dysmorphic disorder. National Clinical Practice Guideline Number 31. British Psychological Society and Royal College of Psychiatrists. 2006. ISBN 1 85433 430 1. (NICE-OCD).
554 Nielsen M, Hansen EH, Gøtzsche PC. What is the difference between dependence and withdrawal reactions? A comparison of benzodiazepines and selective serotonin re-uptake inhibitors. Addict 2012;107:900-8.
555 Behandling af obsessiv-kompulsiv tilstand (OCD). National klinisk retningslinje. København: Sundhedsstyrelsen; 2019.
556 Stein DJ, Carey PD, Lochner C, et al. Escitalopram in obsessive-compulsive disorder: response of symptom dimensions to pharmacotherapy. CNS Spectr 2008;13:492-8.
557 Moraros J, Nwankwo C, Patten SB, et al. The association of antidepressant drug usage with cognitive impairment or dementia, including Alzheimer disease: A systematic review and meta-analysis. Depress Anxiety 2017;34:217-26.
558 Coupland CAC, Hill T, Dening T, et al. Anticholinergic drug exposure and the risk of dementia: a nested case-control study. JAMA Intern Med 2019;179:1084-93.
559 Birks J. Cholinesterase inhibitors for Alzheimer’s disease. Cochrane Database Syst Rev 2006;1:CD005593.
560 Molnar FJ, Man-Son-Hing M, Fergusson D. Systematic review of measures of clinical significance employed in randomized controlled trials of drugs for dementia. J Am Geriatr Soc 2009;57:536-46.
561 FDA package insert for Aricept (donepezil). Accessed 30 April 2022.
562 Syncope with cholinesterase inhibitors. Rev Prescrire 2011;31:434.
563 Tjia J, Briesacher BA, Peterson D, et al. Use of medications of questionable benefit in advanced dementia. JAMA Intern Med 2014;174:1763-71.
564 Screening for dementia. UK National Screening Committee 2014; April.
565 Courtney C, Farrell D, Gray R, et al. Long-term donepezil treatment in 565 patients with Alzheimer’s disease (AD2000): randomised double-blind trial. Lancet 2004;363:2105-15.
566 Letter from Sharon M. Watson to Eisai Medical Research Inc. FDA 2010; Feb 3.
567 Battle CE, Abdul-Rahim AH, Shenkin SD, et al. Cholinesterase inhibitors for vascular dementia and other vascular cognitive impairments: a network meta-analysis. Cochrane Database Syst Rev 2021;2:CD013306.
568 Street JS, Clark WS, Gannon KS, et al. Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. The HGEU Study Group. Arch Gen Psychiatry 2000;57:968-76.
569 Mühlbauer V, Möhler R, Dichter MN, et al. Antipsychotics for agitation and psychosis in people with Alzheimer’s disease and vascular dementia. Cochrane Database Syst Rev 2021;12:CD013304.
570 Saczynski JS, Beiser A, Seshadri S, et al. Depressive symptoms and risk of dementia: the Framingham Heart Study. Neurology 2010;75:35-41.
571 Billioti de Gage S, Moride Y, Ducruet T, et al. Benzodiazepine use and risk of Alzheimer’s disease: case-control study. BMJ 2014;349:g5205.
572 Livingston G, Kelly L, Lewis-Holmes E, et al. Non-pharmacological interventions for agitation in dementia: systematic review of randomised controlled trials. Br J Psychiatry 2014;205:436-42.
573 Read J, Bentall R. The effectiveness of electroconvulsive therapy: a literature review. Epidemiol Psichiatr Soc 2010 Oct-Dec;19:333-47.
574 Carney S, Geddes J. Electroconvulsive therapy. BMJ 2003;326:1343-4.
575 Rose D, Fleischmann P, Wykes T, et al. Patients’ perspectives on electroconvulsive therapy: systematic review. BMJ 2003;326:1363.
576 Tharyan P, Adams CE. Electroconvulsive therapy for schizophrenia. Cochrane Database Syst Rev 2005;2:CD000076.
577 Read J. A response to yet another defence of ECT in the absence of robust efficacy and safety evidence. Epidemiol Psychiatr Sci 2022;31:e13.
578 UK ECT Review Group. Efficacy and safety of electroconvulsive therapy in depressive disorders: a systematic review and meta-analysis. Lancet 2003;361:799-808.
579 Van der Wurff FB, Stek ML, Hoogendijk WL, et al. Electroconvulsive therapy for the depressed elderly. Cochrane Database Syst Rev 2003;2:CD003593.
580 Klinisk vejledning for almen praksis: unipolar depression, diagnostik og behandling. Dansk Selskab for Almen Medicin 2010.
581 Frich M. Brug af elektrochok firedoblet. Jyllands-Posten 1998; May 19.
582 Borre K. Mette’s Voice. Documentary film; 2014.
583 Council of Europe. European Committee for the Prevention of Torture and Inhuman or Degrading Treatment or Punishment (CPT). CPT/Inf/E (2002) 1 – Rev. 2013.
584 Kisely SR, Campbell LA, O’Reilly R. Compulsory community and involuntary outpatient treatment for people with severe mental disorders. Cochrane Database Syst Rev 2017;3:CD004408.
585 Wollaston S. Community treatment orders are not helping people with mental illness. The Guardian 2013; Aug 14.
586 Community treatment orders. Mind 2007; Dec.
587 Fiorillo A, De Rosa C, Del Vecchio V, et al. How to improve clinical practice on involuntary hospital admissions of psychiatric patients: Suggestions from the EUNOMIA study. Eur Psychiat 2011;26:201-7.
588 Scanlan JN. Interventions to reduce the use of seclusion and restraint in inpatient psychiatric settings: what we know so far, a review of the literature. Int J Soc Psychiat 2010;56:412–23.
589 Notat om dosering af lægemidler i psykiatrien. Ministeriet for Sundhed og Forebyggelse 2014; Oct 30.
590 Steinert T, Lepping P, Bernhardsgrütter R, et al. Incidence of seclusion and restraint in psychiatric hospitals: a literature review and survey of international trends. Soc Psychiatry Psychiatr Epidemiol 2010;45:889-97.
591 Nilsonne Å. Processen: möten, mediciner, beslut. Stockholm: Natur & Kultur; 2017.
592 Zinkler M, von Peter S. End coercion in mental health services – toward a system based on support only. Laws 2019;8:19.
593 Gøtzsche PC. Forced drugging with antipsychotics is against the law: decision in Norway. Mad in America 2019; May 4.
594 Gøtzsche PC, Vinther S, Sørensen A. Forced medication in psychiatry: Patients’ rights and the law not respected by Appeals Board in Denmark. Clin Neuropsychiatry 2019;16:229-33.
595 Gøtzsche PC, Sørensen A. Systematic violations of patients’ rights and safety: Forced medication of a cohort of 30 patients. Ind J Med Ethics 2020;Oct-Dec;5(4) NS:312-8.
596 Kingdon D, Young A. Research into putative biological mechanisms of mental disorders has been of no value to clinical psychiatry. Br J Psychiatry 2007;191:285–90.
597 Breggin P. The most dangerous thing you will ever do. Mad in America 2020; Mar 2.
598 Paykel ES, Hart D, Priest RG. Changes in public attitudes to depression during the Defeat Depression Campaign. Br J Psychiatry 1998;173:519-22.
599 Whitaker R, Cosgrove L. Psychiatry under the influence: institutional corruption, social injury, and prescriptions for reform. New York: Palgrave Macmillan; 2015.
600 Nieuwenhuijsen K, Faber B, Verbeek JH, et al. Interventions to improve return to work in depressed people. Cochrane Database Syst Rev 2014;12:CD006237.
601 Nieuwenhuijsen K, Verbeek JH, Neumeyer-Gromen A, et al. Interventions to improve return to work in depressed people. Cochrane Database Syst Rev 2020;10:CD006237.
602 Butler AC, Chapman JE, Forman EM, et al. The empirical status of cognitive-behavioral therapy: a review of meta-analyses. Clin Psychol Rev 2006;26:17-31.
603 Norton PJ, Price EC. A meta-analytic review of adult cognitive-behavioral treatment outcome across the anxiety disorders. J Nerv Ment Dis 2007;195:521-31.
604 Gøtzsche PC. Chemical or psychological psychotherapy? Mad in America 2017; Jan 29.
605 Krupnick JL, Sotsky SM, Simmens S, et al. The role of the therapeutic alliance in psychotherapy and pharmacotherapy outcome: Findings in the National Institute of Mental Health Treatment of Depression Collaborative Research Program. J Consult Clin Psychol 1996;64:532–9.
606 Demyttenaere K, Donneau A-F, Albert A, et al. What is important in being cured from: Does discordance between physicians and patients matter? (2). J Affect Disord 2015;174:372–7.
607 Sørensen A. Withdrawing from antidepressants. PhD thesis. University of Copenhagen. Defended 2022; June 9.
608 Gatenby A. “My anti-depressant withdrawal was worse than depression.” BBC 2020; Mar 12.
609 Read J, Cartwright C, Gibson K. How many of 1829 antidepressant users report withdrawal effects or addiction? Int J Ment Health Nurs 2018;27:1805-15.
610 Sørensen A, Ruhé HG, Munkholm K. The relationship between dose and serotonin transporter occupancy of antidepressants – a systematic review. Mol Psychiatry 2022;27:192-201.
611 Guy A, Davies J, Rizq R (eds.) Guidance for psychological therapists: Enabling conversations with clients taking or withdrawing from prescribed psychiatric drugs. London: APPG for Prescribed Drug Dependence 2019; Dec.
612 Gøtzsche PC, Sørensen A. The review on antidepressant withdrawal that Cochrane won’t publish. Mad in America 2020; Feb 11.
613 Deadly medicines & organised crime. Website.
614 Groot P, van Os J. Antidepressant tapering strips to help people come off medication more safely. Psychosis 2018;10:142-5.
615 Inner Compass Initiative: The Withdrawal Project.
616 Simons P. Peer-support groups were right, guidelines were wrong: Dr. Mark Horowitz on tapering off antidepressants. Mad in America 2019; Mar 20.
617 Healy D. Medical partisans? Why doctors need conflicting interests. Aust N Z J Psychiatry 2012;46:704–7.
618 Bailey RS. FDA corruption charges letter verified. The Los Angeles Post 2012; Apr 8.
619 Letter from FDA scientists to President Barrack Obama. 2009; Apr 2.
620 Lichtblau E, Shane S. Vast FDA effort tracked e-mails of its scientists. New York Times 2012; July 14.
621 Danish drugmaker Lundbeck A/S and Japanese partner Takeda Pharmaceutical Co have submitted a new antidepressant for regulatory approval in the United States. Reuters 2012; Oct 2.
622 Abraham J. Science, politics and the pharmaceutical industry. London: UCL Press; 1995.
623 Davis JM, Giakas WJ, Qu J, et al. Should we treat depression with drugs or psychological interventions? A reply to Ioannidis. Philos Ethics Humanit Med 2011;6:8.
624 Glenthøj B, Baandrup L, Ebdrup B, et al. Bag myterne om antipsykotisk medicin. Politiken 2012; Oct 19.
625 Schmidt AL. Psykiaterformand: Overlæges forslag vil føre til flere selvmord. Politiken 2014; Jan 6.
626 Licht R, Nordentoft M, Bech P, et al. Ti veje til bedre psykiatrisk behandling. Altinget 2014; Feb 6.
627 Sharfstein S. Big Pharma and American psychiatry: The good, the bad and the ugly. Psychiatric News 2005;40:3.
628 Causes – Attention deficit hyperactivity disorder (ADHD). National Health Service. Accessed 4 July 2022.
629 Riksdagens Ombudsman. Kritik mot Göteborgs universitet for handläggningen av en begäran om utlämnande av allmänna handlingar m.m. 2017; Dec 20:Dnr 7571-2016.
630 Gøtzsche PC. Vaccines: truth, lies, and controversy. New York: Skyhorse; 2021.
631 Whitaker R. Video of talk presented at the inaugural symposium for the Institute for Scientific Freedom. Copenhagen 2019; Mar 9.
632 Stordrange IL. The happy pill. She survived 10 years of ”torture” in psychiatry. Documentary film 2017; Apr 16.
633 Hoel A. Cause of death: unknown. Documentary film 2017; Mar 24.
634 Ditzel EE. Psykiatri-professor om DR-historier: ”Skræmmekampagne der kan koste liv.” Journalisten 2013; Apr 11.
635 Gøtzsche PC. Death of a whistleblower and Cochrane’s moral collapse. Copenhagen: People’s Press; 2019.
636 Pedersen AT. Diagnosing psychiatry. Documentary film 2019; Jan 29.
637 Spencer M. The Carter Center’s guide for mental health journalism: don’t question, follow the script. Mad in America 2020; Feb 23.
638 Kleinman A. Rebalancing academic psychiatry: why it needs to happen – and soon. Br J Psychiatry 2012;201:421–2
639 Harris G, Carey B, Roberts J. Psychiatrists, children and drug industry’s role. New York Times 2007; May 10.
640 Moynihan R. Is the relationship between pharma and medical education on the rocks? BMJ 2008;337:484-5.
641 Schelin EM. Sund skepsis er den bedste medicin. Ugeskr Læger 2010;172:3361.
642 Campbell EG, Weissman JS, Ehringhaus S, et al. Institutional academic industry relationships. JAMA 2007;298:1779-86.
643 Braithwaite J. Corporate crime in the pharmaceutical industry. London: Routledge & Kegan Paul; 1984.
644 Wakefield JC. Misdiagnosing normality: Psychiatry’s failure to address the problem of false positive diagnoses of mental disorder in a changing professional environment. J Ment Health 2010;19:337-51.
645 Schizotypal Personality Disorder Test. Accessed 5 June 2020.
646 Schizotypal personality disorder. Mayo Clinic. Accessed 5 June 2020.
647 Pigott HE, Leventhal AM, Alter GS, et al. Efficacy and effectiveness of antidepressants: current status of research. Psychother Psychosom 2010;79:267-79.
648 Whitaker R. The STAR*D scandal: a new paper sums it all up. Mad in America 2010; Aug 27.
649 Pigott E. STAR*D: Adding fiction to fiction. Mad in America 2011; Apr 10.
650 Whitaker R. Thomas Insel makes a case for abolishing psychiatry. Mad in America 2022; Apr 30.
651 Insel T. Healing: our path from mental illness to mental health. New York: Penguin Press; 2022.
652 Bockoven JS, Solomon HC. Comparison of two five-year follow-up studies: 1947 to 1952 and 1967 to 1972. Am J Psychiatry 1975;132:796-801.
653 Carpenter WT, McGlashan TH, Strauss JS. The treatment of acute schizophrenia without drugs: an investigation of some current assumptions. Am J Psychiatry 1977;134:14-20.
654 Bola JR, Mosher LR. Treatment of acute psychosis without neuroleptics: two-year outcomes from the Soteria project. J Nerv Ment Dis 2003;191:219-29.
655 Rappaport M, Hopkins HK, Hall K, et al. Are there schizophrenics for whom drugs may be unnecessary or contraindicated? Int Pharmacopsychiatry 1978;13:100-11.
656 Chouinard G, Jones BD. Neuroleptic-induced supersensitivity psychosis: clinical and pharmacologic characteristics. Am J Psychiatry 1980;137:16-21.
657 Ho BC, Andreasen NC, Nopoulos P, et al. Progressive structural brain abnormalities and their relationship to clinical outcome: a longitudinal magnetic resonance imaging study early in schizophrenia. Arch Gen Psychiatry 2003;60:585-94.
658 Harrow M, Jobe TH. Factors involved in outcome and recovery in schizophrenia patients not on antipsychotic medications: a 15-year multifollow-up study. J Nerv Ment Dis 2007;195:406-14.
659 Harrow M, Jobe TH, Faull RN. Does treatment of schizophrenia with antipsychotic medications eliminate or reduce psychosis? A 20-year multi-follow-up study. Psychol Med 2014;44:3007-16.
660 Moilanen J, Haapea M, Miettunen J, et al. Characteristics of subjects with schizophrenia spectrum disorder with and without antipsychotic medication – a 10-year follow-up of the Northern Finland 1966 Birth Cohort study. Eur Psychiatry 2013;28:53-8.
661 Gleeson JF, Cotton SM, Alvarez-Jimenez M, et al. A randomized controlled trial of relapse prevention therapy for first-episode psychosis patients: outcome at 30-month follow-up. Schizophr Bull 2013;39:436-48.
662 Wils RS, Gotfredsen DR, Hjorthøj C, et al. Antipsychotic medication and remission of psychotic symptoms 10 years after a first-episode psychosis. Schizophr Res 2017;182:42-8.
663 Jung E, Wiesjahn M, Wendt H, et al. Symptoms, functioning and coping strategies in individuals with schizophrenia spectrum disorders who do not take antipsychotic medication: a comparative interview study. Psychol Med 2016;46:2179-88.
664 Bjornestad J, Lavik KO, Davidson L, et al. Antipsychotic treatment – a systematic literature review and meta-analysis of qualitative studies. J Ment Health 2020;29:513-23.
665 Whitaker R. Drug info: Adults. Antidepressants. Mad in America. Undated.
666 Posternak MA, Solomon DA, Leon AC, et al. The naturalistic course of unipolar major depression in the absence of somatic therapy. J Nerv Ment Dis 2006;194:324-9.
667 Shea MT, Elkin I, Imber SD, et al. Course of depressive symptoms over follow-up. Findings from the National Institute of Mental Health Treatment of Depression Collaborative Research Program. Arch Gen Psychiatry 1992;49:782-7.
668 Coryell W, Endicott J, Winokur G, et al. Characteristics and significance of untreated major depressive disorder. Am J Psychiatry 1995;152:1124-9.
669 Goldberg D, Privett M, Ustun B, et al. The effects of detection and treatment on the outcome of major depression in primary care: a naturalistic study in 15 cities. Br J Gen Pract 1998;48:1840-4.
670 Dewa CS, Hoch JS, Lin E, et al. Pattern of antidepressant use and duration of depression-related absence from work. Br J Psychiatry 2003;183:507-13.
671 Patten SB. The impact of antidepressant treatment on population health: synthesis of data from two national data sources in Canada. Popul Health Metr 2004;2:9.
672 Vittengl JR. Poorer long-term outcomes among persons with major depressive disorder treated with medication. Psychother Psychosom 2017;86:302-4.
673 Hengartner MP, Angst J, Rössler W. Antidepressant use prospectively relates to a poorer long-term outcome of depression: results from a prospective community cohort study over 30 years. Psychother Psychosom 2018;87:181-3.
674 Fava GA. Do antidepressant and antianxiety drugs increase chronicity in affective disorders? Psychother Psychosom 1994;61:125-31.
675 Fava GA. Holding on: depression, sensitization by antidepressant drugs, and the prodigal experts. Psychother Psychosom 1995;64:57-61.
676 Fava GA. Potential sensitising effects of antidepressant drugs on depression. CNS Drugs 1999;4:247-56.
677 Fava GA. Can long-term treatment with antidepressant drugs worsen the course of depression? J Clin Psychiatry 2003;64:123-33.
678 El-Mallakh RS, Gao Y, Jeannie Roberts R. Tardive dysphoria: the role of long term antidepressant use in-inducing chronic depression. Med Hypotheses 2011;76:769-73.
679 Raine ADHD Study: Long-term outcomes associated with stimulant medication in the treatment of ADHD in children. Government of Western Australia 2010; Feb 7.
680 Currie J, Stabile M, Jones LE. Do stimulant medications improve educational and behavioral outcomes for children with ADHD? National Bureau of Economic Research 2013; June.
681 Questions and answers about the NIMH Sequenced Treatment Alternatives to Relieve Depression (STAR*D) Study — Level 1 results, published in American Journal of Psychiatry · January 1, 2006. NIMH press release 2006; Jan.
682 The Multimodal Treatment of Attention Deficit Hyperactivity Disorder Study (MTA): Questions and answers. NIMH 2009; Nov.
683 Allen Frances tweet. 2019; July 29.
684 Greenberg G. The rats of NIMH. The New Yorker 2013; May 16.
685 Hyman SE. The diagnosis of mental disorders: the problem of reification. Annu Rev Clin Psychol 2010;6:155-79.
686 Wikler D. “A crisis in medical professionalism.” In: Ethics and the Business of Biomedicine (D. Arnold, ed.). New York: Cambridge University Press; 2009:253.
687 Knipe D, Padmanathan P, Newton-Howes G, et al. Suicide and self-harm. Lancet 2022;399:1903-16.
688 Gøtzsche PC. A hopelessly flawed seminar in “The Lancet” about suicide. Mad in America 2022; June 1.
689 Goldney RD. Suicide and antidepressants: what is the evidence? Aust N Z J Psychiatry 2006;40:381-5.
690 Zahl PH, De Leo D, Ekeberg Ø, et al. The relationship between sales of SSRI, TCA and suicide rates in the Nordic countries. BMC Psychiatry 2010;10:62.
691 Mann JJ, Michel CA, Auerbach RP. Improving suicide prevention through evidence-based strategies: a systematic review. Am J Psychiatry 2021;178:611-24.
692 Smith R. Medical journals are an extension of the marketing arm of pharmaceutical companies. PLoS Med 2005;2:e138.
693 Keller MB, McCullough JP, Klein DN et al. A comparison of nefazodone, the cognitive behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic depression. N Engl J Med 2000;342:1462-70.
694 Angell M. Is academic medicine for sale? N Engl J Med 2000; 342:1516-8.
695 Healy D. Reply to D. Wilkinson – Loss of anxiety and increased aggression in a 15-year-old boy taking fluoxetine. J Psychopharmacol 1999;13:421.
696 ISEPP calls for a Federal Investigation into the link between Psychotropic Drugs and Mass Murder. International Society for Ethical Psychology and Psychiatry 2013; Jan 4.
697 Brody H. Hooked: ethics, the medical profession, and the pharmaceutical industry. Lanham: Rowman & Littlefield; 2008.
698 Kessler RC, Demler O, Frank RG, et al. Prevalence and treatment of mental disorders, 1990 to 2003. N Engl J Med 2005;352:2515–23.
699 Spence D. The psychiatric oligarchs who medicalise normality. BMJ 2012;344:e3135.
700 Gøtzsche PC. Unwarranted criticism of “Psychiatry cone astray.” Mad in America 2014; Feb 20.
701 Brogaard M. Depressive eksperimenterer med medicinen. Videnskab.dk 2014; Dec 28.